TWI374036B - Flexible bone composite - Google Patents
Flexible bone composite Download PDFInfo
- Publication number
- TWI374036B TWI374036B TW094119113A TW94119113A TWI374036B TW I374036 B TWI374036 B TW I374036B TW 094119113 A TW094119113 A TW 094119113A TW 94119113 A TW94119113 A TW 94119113A TW I374036 B TWI374036 B TW I374036B
- Authority
- TW
- Taiwan
- Prior art keywords
- polymer
- calcium
- layer
- polymer layer
- flexible bone
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title claims description 169
- 210000000988 bone and bone Anatomy 0.000 title claims description 148
- 229920000642 polymer Polymers 0.000 claims description 275
- 239000011575 calcium Substances 0.000 claims description 92
- 229910052791 calcium Inorganic materials 0.000 claims description 88
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 87
- 229940043430 calcium compound Drugs 0.000 claims description 62
- 150000001674 calcium compounds Chemical class 0.000 claims description 62
- 239000002245 particle Substances 0.000 claims description 43
- 229920001059 synthetic polymer Polymers 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 239000001506 calcium phosphate Substances 0.000 claims description 10
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 10
- 235000011010 calcium phosphates Nutrition 0.000 claims description 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 6
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000002599 Smear Layer Diseases 0.000 claims 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 claims 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 239000010410 layer Substances 0.000 description 302
- 238000000034 method Methods 0.000 description 40
- 229920001577 copolymer Polymers 0.000 description 38
- -1 poly(ethylene oxide) Polymers 0.000 description 37
- 239000013047 polymeric layer Substances 0.000 description 17
- 239000004599 antimicrobial Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229940124530 sulfonamide Drugs 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 239000000178 monomer Substances 0.000 description 13
- 230000007547 defect Effects 0.000 description 12
- 238000002513 implantation Methods 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 239000011148 porous material Substances 0.000 description 12
- 239000003102 growth factor Substances 0.000 description 11
- 238000004080 punching Methods 0.000 description 10
- 150000003456 sulfonamides Chemical class 0.000 description 10
- 239000000052 vinegar Substances 0.000 description 10
- 235000021419 vinegar Nutrition 0.000 description 10
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 9
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940124587 cephalosporin Drugs 0.000 description 6
- 150000001780 cephalosporins Chemical class 0.000 description 6
- 238000007334 copolymerization reaction Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 5
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000013067 intermediate product Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000002639 bone cement Substances 0.000 description 4
- 235000011132 calcium sulphate Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 3
- 229950006704 aldesulfone Drugs 0.000 description 3
- NEDPPCHNEOMTJV-UHFFFAOYSA-N aldesulfone Chemical compound C1=CC(NCS(=O)O)=CC=C1S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1 NEDPPCHNEOMTJV-UHFFFAOYSA-N 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229960000860 dapsone Drugs 0.000 description 3
- 210000003298 dental enamel Anatomy 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 230000009477 glass transition Effects 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229960000654 sulfafurazole Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 2
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 2
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 2
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 2
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 2
- JYZJYKOZGGEXSX-UHFFFAOYSA-N 2-hydroxymyristic acid Chemical compound CCCCCCCCCCCCC(O)C(O)=O JYZJYKOZGGEXSX-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- SAVXTCZPVGDUCR-UHFFFAOYSA-N 4-[4-(4-aminophenyl)sulfonylanilino]-4-oxobutanoic acid;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(NC(=O)CCC(O)=O)C=C1 SAVXTCZPVGDUCR-UHFFFAOYSA-N 0.000 description 2
- SVYBEBLNQGDRHF-UHFFFAOYSA-N 4-amino-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide Chemical compound S1C(CC)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 SVYBEBLNQGDRHF-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- KHFUQWURHSKTPO-LBYUQGKWSA-N CC(C)c1cc(\N=N\c2ccc(cc2)S(=O)(=O)c2ccc(cc2)\N=N\c2cc(C(C)C)c(O)cc2C)c(C)cc1O Chemical compound CC(C)c1cc(\N=N\c2ccc(cc2)S(=O)(=O)c2ccc(cc2)\N=N\c2cc(C(C)C)c(O)cc2C)c(C)cc1O KHFUQWURHSKTPO-LBYUQGKWSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 229930182843 D-Lactic acid Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010026389 Gramicidin Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- MIFYHUACUWQUKT-UHFFFAOYSA-N Isopenicillin N Natural products OC(=O)C1C(C)(C)SC2C(NC(=O)CCCC(N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-UHFFFAOYSA-N 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 229930195708 Penicillin V Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 2
- QKLSCPPJEVXONT-UHFFFAOYSA-N Sulfametomidine Chemical compound CC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QKLSCPPJEVXONT-UHFFFAOYSA-N 0.000 description 2
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229950009438 acedapsone Drugs 0.000 description 2
- 229950008644 adicillin Drugs 0.000 description 2
- 229960003204 amorolfine Drugs 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960002278 azidamfenicol Drugs 0.000 description 2
- SGRUZFCHLOFYHZ-MWLCHTKSSA-N azidamfenicol Chemical compound [N-]=[N+]=NCC(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 SGRUZFCHLOFYHZ-MWLCHTKSSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000003490 calendering Methods 0.000 description 2
- 229960004602 capreomycin Drugs 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960004287 clofazimine Drugs 0.000 description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940022769 d- lactic acid Drugs 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 229950002043 diathymosulfone Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- NLLGJEMIZSAJFN-AAFOHLTDSA-L disodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-1-[4-[4-[[(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxy-1-sulfonatohexyl]amino]phenyl]sulfonylanilino]hexane-1-sulfonate Chemical compound [Na+].[Na+].C1=CC(NC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)S([O-])(=O)=O)=CC=C1S(=O)(=O)C1=CC=C(NC([C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)S([O-])(=O)=O)C=C1 NLLGJEMIZSAJFN-AAFOHLTDSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960004213 erythromycin lactobionate Drugs 0.000 description 2
- 229960004142 erythromycin stearate Drugs 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229950009858 glucosulfone Drugs 0.000 description 2
- 229960003758 glycobiarsol Drugs 0.000 description 2
- FATAHBJTOKXSDH-UHFFFAOYSA-M glycobiarsol Chemical compound OCC(=O)NC1=CC=C([As](O)(=O)O[Bi]=O)C=C1 FATAHBJTOKXSDH-UHFFFAOYSA-M 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940116871 l-lactate Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 229960001914 paromomycin Drugs 0.000 description 2
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 2
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229940056367 penicillin v Drugs 0.000 description 2
- 229960003187 penimepicycline Drugs 0.000 description 2
- MEGKRPMNPGTIIG-VNYBMUHKSA-N penimepicycline Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1.O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCN(CCO)CC1 MEGKRPMNPGTIIG-VNYBMUHKSA-N 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- ABBQGOCHXSPKHJ-WUKNDPDISA-N prontosil Chemical compound NC1=CC(N)=CC=C1\N=N\C1=CC=C(S(N)(=O)=O)C=C1 ABBQGOCHXSPKHJ-WUKNDPDISA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960000260 solasulfone Drugs 0.000 description 2
- WAGUNVVOQBKLDL-UHFFFAOYSA-J solasulfone Chemical compound [Na+].[Na+].[Na+].[Na+].C=1C=C(S(=O)(=O)C=2C=CC(NC(CC(C=3C=CC=CC=3)S([O-])(=O)=O)S([O-])(=O)=O)=CC=2)C=CC=1NC(S(=O)(=O)[O-])CC(S([O-])(=O)=O)C1=CC=CC=C1 WAGUNVVOQBKLDL-UHFFFAOYSA-J 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229950008210 succisulfone Drugs 0.000 description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 2
- 229960005256 sulbactam Drugs 0.000 description 2
- 229960001343 sulfachrysoidine Drugs 0.000 description 2
- ZELCNSAUMHNSSU-ISLYRVAYSA-N sulfachrysoidine Chemical compound OC(=O)c1cc(N)cc(N)c1\N=N\c1ccc(S(N)(=O)=O)cc1 ZELCNSAUMHNSSU-ISLYRVAYSA-N 0.000 description 2
- 229950009341 sulfadiasulfone Drugs 0.000 description 2
- RAMPGXSXWLFXFU-UHFFFAOYSA-N sulfadiasulfone Chemical compound CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 RAMPGXSXWLFXFU-UHFFFAOYSA-N 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- XRVJPLDTMUSSDE-UHFFFAOYSA-N sulfadicramide Chemical compound CC(C)=CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 XRVJPLDTMUSSDE-UHFFFAOYSA-N 0.000 description 2
- 229960002953 sulfadicramide Drugs 0.000 description 2
- 229960000973 sulfadimethoxine Drugs 0.000 description 2
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 2
- 229960002135 sulfadimidine Drugs 0.000 description 2
- 229960004673 sulfadoxine Drugs 0.000 description 2
- 229960003288 sulfaethidole Drugs 0.000 description 2
- 229950008582 sulfaguanole Drugs 0.000 description 2
- IJZUQDQOAFUFJY-UHFFFAOYSA-N sulfaguanole Chemical compound O1C(C)=C(C)N=C1N\C(N)=N\S(=O)(=O)C1=CC=C(N)C=C1 IJZUQDQOAFUFJY-UHFFFAOYSA-N 0.000 description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 2
- 229960005158 sulfamethizole Drugs 0.000 description 2
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 2
- 229960004936 sulfamethoxypyridazine Drugs 0.000 description 2
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 2
- 229960001873 sulfametomidine Drugs 0.000 description 2
- 229960002229 sulfametoxydiazine Drugs 0.000 description 2
- 229950008188 sulfamidochrysoidine Drugs 0.000 description 2
- 229960001363 sulfamoxole Drugs 0.000 description 2
- CYFLXLSBHQBMFT-UHFFFAOYSA-N sulfamoxole Chemical compound O1C(C)=C(C)N=C1NS(=O)(=O)C1=CC=C(N)C=C1 CYFLXLSBHQBMFT-UHFFFAOYSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 description 2
- 239000012855 volatile organic compound Substances 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- XBNDESPXQUOOBQ-LSMLZNGOSA-N (2r,3s)-4-[[(2s)-1-[[2-[[(2s)-1-[[2-[[(2r,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-[(3s,9ar)-1,4-dioxo-3,6,7,8,9,9a-hexahydro-2h-pyrido[1,2-a]pyrazin-3-yl]ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-3-amino-1-oxobutan-2-yl]amino]-2-oxoethyl]am Chemical compound CCC(C)CCCCC\C=C\CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H]([C@H](C)N)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)[C@H]1C(=O)N2CCCC[C@@H]2C(=O)N1 XBNDESPXQUOOBQ-LSMLZNGOSA-N 0.000 description 1
- ZHIKHAVOCHJPNC-SQAHNGQVSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl]oxyoxane-3,4-diol;undec-10-enoic acid Chemical compound OC(=O)CCCCCCCCC=C.N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N ZHIKHAVOCHJPNC-SQAHNGQVSA-N 0.000 description 1
- QCFJTUGHFMTKSB-LQDWTQKMSA-N (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 QCFJTUGHFMTKSB-LQDWTQKMSA-N 0.000 description 1
- NLFFJIIRAGZISV-LKMNLCDCSA-N (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide (3R,4R)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-2-amino-6-hydroxy-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide (3R,4R)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R)-2-amino-1,4,5,6-tetrahydropyrimidin-4-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide Chemical compound NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1.NCC[C@@H](O)[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)[C@H]1CCN=C(N)N1.NCC[C@@H](O)[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)=C\NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 NLFFJIIRAGZISV-LKMNLCDCSA-N 0.000 description 1
- HPWIIERXAFODPP-GHBBWTPBSA-N (3r,4r)-3,6-diamino-n-[(3s,6z,9s,12s,15s)-3-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]-4-hydroxyhexanamide Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)[C@H](O)CCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)NCC1 HPWIIERXAFODPP-GHBBWTPBSA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- MTCQOMXDZUULRV-ADOAZJKMSA-N (4s,4as,5ar,12ar)-4-(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O MTCQOMXDZUULRV-ADOAZJKMSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- FAMUIRDLAWWMCQ-AQFAATAFSA-N (4s,4as,5as,6s,12ar)-n-[[4-[n-(diaminomethylidene)carbamimidoyl]piperazin-1-yl]methyl]-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound OC([C@@]1(O)C(=O)C=2[C@@H]([C@](C3=CC=CC(O)=C3C=2O)(C)O)C[C@H]1[C@@H](C1=O)N(C)C)=C1C(=O)NCN1CCN(C(=N)N=C(N)N)CC1 FAMUIRDLAWWMCQ-AQFAATAFSA-N 0.000 description 1
- XSPUSVIQHBDITA-KXDGEKGBSA-N (6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-KXDGEKGBSA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- JIABEENURMZTTI-UHFFFAOYSA-N 1-isocyanato-2-[(2-isocyanatophenyl)methyl]benzene Chemical class O=C=NC1=CC=CC=C1CC1=CC=CC=C1N=C=O JIABEENURMZTTI-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- CMBCIHJRGFZBCO-UHFFFAOYSA-N 1H-1,2-benzodiazepine-3-sulfonamide Chemical compound N1N=C(C=CC2=C1C=CC=C2)S(=O)(=O)N CMBCIHJRGFZBCO-UHFFFAOYSA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- HNRMPXKDFBEGFZ-UHFFFAOYSA-N 2,2-dimethylbutane Chemical compound CCC(C)(C)C HNRMPXKDFBEGFZ-UHFFFAOYSA-N 0.000 description 1
- WVPAABNYMHNFJG-QDVBXLKVSA-N 2,2-dimethylpropanoyloxymethyl (6r,7r)-7-[[(z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 WVPAABNYMHNFJG-QDVBXLKVSA-N 0.000 description 1
- NFTOEHBFQROATQ-UHFFFAOYSA-N 2,3-dihydrofuran-5-carboxylic acid Chemical compound OC(=O)C1=CCCO1 NFTOEHBFQROATQ-UHFFFAOYSA-N 0.000 description 1
- MSJBLPVXRJMJSY-UHFFFAOYSA-N 2,6-bis(2-ethylhexyl)-7a-methyl-1,3,5,7-tetrahydroimidazo[1,5-c]imidazole Chemical compound C1N(CC(CC)CCCC)CC2(C)CN(CC(CC)CCCC)CN21 MSJBLPVXRJMJSY-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- CNDCQWGRLNGNNO-UHFFFAOYSA-N 2-(2-sulfanylethoxy)ethanethiol Chemical compound SCCOCCS CNDCQWGRLNGNNO-UHFFFAOYSA-N 0.000 description 1
- AFKRZUUZFWTBCC-WSTZPKSXSA-N 2-(diethylamino)ethyl (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCCN(CC)CC)C(=O)CC1=CC=CC=C1 AFKRZUUZFWTBCC-WSTZPKSXSA-N 0.000 description 1
- DYCJFJRCWPVDHY-UHFFFAOYSA-N 2-(hydroxymethyl)-5-[6-[(4-nitrophenyl)methylsulfanyl]purin-9-yl]oxolane-3,4-diol Chemical compound OC1C(O)C(CO)OC1N1C2=NC=NC(SCC=3C=CC(=CC=3)[N+]([O-])=O)=C2N=C1 DYCJFJRCWPVDHY-UHFFFAOYSA-N 0.000 description 1
- HQVZOORKDNCGCK-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methyl]-4-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(CC=2C(=CC(Cl)=CC=2)Cl)=C1 HQVZOORKDNCGCK-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 description 1
- HVHVTGIAAGQNOB-UHFFFAOYSA-N 2-[[4-(carbamoylamino)phenyl]-(2-carboxyphenyl)sulfanylarsanyl]sulfanylbenzoic acid Chemical compound C1=CC(NC(=O)N)=CC=C1[As](SC=1C(=CC=CC=1)C(O)=O)SC1=CC=CC=C1C(O)=O HVHVTGIAAGQNOB-UHFFFAOYSA-N 0.000 description 1
- VULRLPILKVVAQO-UHFFFAOYSA-N 2-[[4-(carbamoylamino)phenyl]-(carboxymethylsulfanyl)arsanyl]sulfanylacetic acid Chemical compound NC(=O)NC1=CC=C([As](SCC(O)=O)SCC(O)=O)C=C1 VULRLPILKVVAQO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 1
- RGMMREBHCYXQMA-UHFFFAOYSA-N 2-hydroxyheptanoic acid Chemical compound CCCCCC(O)C(O)=O RGMMREBHCYXQMA-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxyoctadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 1
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- ULKFLOVGORAZDI-UHFFFAOYSA-N 3,3-dimethyloxetan-2-one Chemical compound CC1(C)COC1=O ULKFLOVGORAZDI-UHFFFAOYSA-N 0.000 description 1
- LSBIUXKNVUBKRI-UHFFFAOYSA-N 4,6-dimethylpyrimidine Chemical compound CC1=CC(C)=NC=N1 LSBIUXKNVUBKRI-UHFFFAOYSA-N 0.000 description 1
- HLCZHPINLSRYNY-UHFFFAOYSA-N 4-[4-(aminomethyl)phenyl]sulfonylaniline Chemical compound C1=CC(CN)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 HLCZHPINLSRYNY-UHFFFAOYSA-N 0.000 description 1
- GCQZFVAHUZIDRP-UHFFFAOYSA-N 4-amino-n-(4-sulfamoylphenyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=C(S(N)(=O)=O)C=C1 GCQZFVAHUZIDRP-UHFFFAOYSA-N 0.000 description 1
- YEAICDDXRUOCKJ-UHFFFAOYSA-N 4-amino-n-pyrazin-2-ylbenzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=CC=N1 YEAICDDXRUOCKJ-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- IGEBVIHXQMFYPD-UHFFFAOYSA-N 4-methyl-1,3-dioxolan-2-one oxepan-2-one Chemical compound C1(CCCCCO1)=O.C1(OCC(C)O1)=O IGEBVIHXQMFYPD-UHFFFAOYSA-N 0.000 description 1
- YVQVOQKFMFRVGR-VGOFMYFVSA-N 5-(morpholin-4-ylmethyl)-3-[(e)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OC(CN2CCOCC2)C1 YVQVOQKFMFRVGR-VGOFMYFVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- GXCRUTWHNMMJEK-WYUVZMMLSA-M Cefacetrile sodium Chemical compound [Na+].S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 GXCRUTWHNMMJEK-WYUVZMMLSA-M 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- DTGZHCFJNDAHEN-YSFUMNCJSA-N Cephaeline Natural products O(C)c1c(OC)cc2c([C@H]3N(C[C@@H](CC)[C@@H](C[C@H]4NCCc5c4cc(OC)c(O)c5)C3)CC2)c1 DTGZHCFJNDAHEN-YSFUMNCJSA-N 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- FZNXAQMQVKBXDR-UHFFFAOYSA-N Diamthazole dihydrochloride Chemical compound Cl.Cl.CCN(CC)CCOC1=CC=C2N=C(N(C)C)SC2=C1 FZNXAQMQVKBXDR-UHFFFAOYSA-N 0.000 description 1
- QFVAWNPSRQWSDU-UHFFFAOYSA-N Dibenzthion Chemical compound C1N(CC=2C=CC=CC=2)C(=S)SCN1CC1=CC=CC=C1 QFVAWNPSRQWSDU-UHFFFAOYSA-N 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 108010038532 Enviomycin Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 229930195503 Fortimicin Natural products 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 description 1
- LZKVXMYVBSNXER-YZPKDWIXSA-N Glaucarubin Chemical compound O[C@@H]([C@]1(C)[C@@H]23)[C@@H](O)C=C(C)[C@@H]1C[C@@H]1[C@@]43CO[C@@]2(O)[C@H](O)[C@H](C)[C@@H]4[C@@H](OC(=O)[C@@](C)(O)CC)C(=O)O1 LZKVXMYVBSNXER-YZPKDWIXSA-N 0.000 description 1
- LZKVXMYVBSNXER-UHFFFAOYSA-N Glaucarubin Natural products C12C3(C)C(O)C(O)C=C(C)C3CC3C41COC2(O)C(O)C(C)C4C(OC(=O)C(C)(O)CC)C(=O)O3 LZKVXMYVBSNXER-UHFFFAOYSA-N 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 239000005795 Imazalil Substances 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- 108010046774 Mikamycin Proteins 0.000 description 1
- 229930192051 Mikamycin Natural products 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GWBPFRGXNGPPMF-UHFFFAOYSA-N N-[4-[(4-nitrophenyl)sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1 GWBPFRGXNGPPMF-UHFFFAOYSA-N 0.000 description 1
- OMRDSWJXRLDPBB-UHFFFAOYSA-N N=C=O.N=C=O.C1CCCCC1 Chemical compound N=C=O.N=C=O.C1CCCCC1 OMRDSWJXRLDPBB-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- VSVAVMVWTLLTCH-BJMVGYQFSA-N Nifuradene Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NCC1 VSVAVMVWTLLTCH-BJMVGYQFSA-N 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 239000004186 Penicillin G benzathine Substances 0.000 description 1
- 239000004105 Penicillin G potassium Substances 0.000 description 1
- 239000004185 Penicillin G procaine Substances 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000562 Poly(ethylene adipate) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010079780 Pristinamycin Proteins 0.000 description 1
- RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 description 1
- NJCJBUHJQLFDSW-UHFFFAOYSA-N Rufloxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 NJCJBUHJQLFDSW-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZLYHTQKHXIVMLY-UHFFFAOYSA-N Sulfatolamide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1.NC(=S)NS(=O)(=O)C1=CC=C(N)C=C1 ZLYHTQKHXIVMLY-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229930185860 Tuberactinomycin Natural products 0.000 description 1
- 108050009309 Tuberin Proteins 0.000 description 1
- 102000044633 Tuberous Sclerosis Complex 2 Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010076164 Tyrocidine Proteins 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102400001190 Vastatin Human genes 0.000 description 1
- 101800000422 Vastatin Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- 239000004110 Zinc silicate Substances 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- WWXBHTZSYYGCSG-UHFFFAOYSA-N [4-(carbamoylamino)phenyl]arsonic acid Chemical compound NC(=O)NC1=CC=C([As](O)(O)=O)C=C1 WWXBHTZSYYGCSG-UHFFFAOYSA-N 0.000 description 1
- FKKUMFTYSTZUJG-UHFFFAOYSA-N acediasulfone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(NCC(O)=O)C=C1 FKKUMFTYSTZUJG-UHFFFAOYSA-N 0.000 description 1
- 229950010964 acediasulfone Drugs 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 229960004124 acrisorcin Drugs 0.000 description 1
- YZODJQFXMFEJRM-UHFFFAOYSA-N acrisorcin Chemical compound CCCCCCC1=CC=C(O)C=C1O.C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 YZODJQFXMFEJRM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940024554 amdinocillin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940072174 amphenicols Drugs 0.000 description 1
- 108010079465 amphomycin Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- CGBVAVUSGPAZRX-UHFFFAOYSA-N aniline 2-hydroxybenzoic acid Chemical compound NC1=CC=CC=C1.C(C=1C(O)=CC=CC1)(=O)O CGBVAVUSGPAZRX-UHFFFAOYSA-N 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000398 anti-amebic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- XMQVYNAURODYCQ-SLFBBCNNSA-N apalcillin Chemical compound C1([C@@H](NC(=O)C=2C(=C3N=CC=CC3=NC=2)O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 XMQVYNAURODYCQ-SLFBBCNNSA-N 0.000 description 1
- 229950001979 apalcillin Drugs 0.000 description 1
- HRWVXKVRSNICJQ-GMJIGYHYSA-N apicycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NC(C(O)=O)N1CCN(CCO)CC1 HRWVXKVRSNICJQ-GMJIGYHYSA-N 0.000 description 1
- 229950008405 apicycline Drugs 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 229960005397 arbekacin Drugs 0.000 description 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N arbekacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 description 1
- 229960000778 arsthinol Drugs 0.000 description 1
- MRUDSZSRLQAPOG-UHFFFAOYSA-N arsthinol Chemical compound C1=C(O)C(NC(=O)C)=CC([As]2SC(CO)CS2)=C1 MRUDSZSRLQAPOG-UHFFFAOYSA-N 0.000 description 1
- 229960000202 aspoxicillin Drugs 0.000 description 1
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 description 1
- 229960004328 azidocillin Drugs 0.000 description 1
- ODFHGIPNGIAMDK-NJBDSQKTSA-N azidocillin Chemical compound C1([C@@H](N=[N+]=[N-])C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 ODFHGIPNGIAMDK-NJBDSQKTSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical class O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 description 1
- 229940100627 bambermycins Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JAQPGQYDZJZOIN-LQDWTQKMSA-N benzylpenicillin benethamine Chemical compound C=1C=CC=CC=1C[NH2+]CCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 JAQPGQYDZJZOIN-LQDWTQKMSA-N 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- DQNIWUUHJSXGHW-UHFFFAOYSA-N bialamicol Chemical compound C=CCC1=C(O)C(CN(CC)CC)=CC(C=2C=C(CN(CC)CC)C(O)=C(CC=C)C=2)=C1 DQNIWUUHJSXGHW-UHFFFAOYSA-N 0.000 description 1
- 229950000260 bialamicol Drugs 0.000 description 1
- 229960003169 biapenem Drugs 0.000 description 1
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000000071 blow moulding Methods 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 229960000252 brodimoprim Drugs 0.000 description 1
- BFCRRLMMHNLSCP-UHFFFAOYSA-N brodimoprim Chemical compound COC1=C(Br)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 BFCRRLMMHNLSCP-UHFFFAOYSA-N 0.000 description 1
- 229960000712 bromochlorosalicylanilide Drugs 0.000 description 1
- QBSGXIBYUQJHMJ-UHFFFAOYSA-N bromochlorosalicylanilide Chemical compound OC1=CC=C(Br)C=C1C(=O)NC1=CC=C(Cl)C=C1 QBSGXIBYUQJHMJ-UHFFFAOYSA-N 0.000 description 1
- ZGJHIFYEQJEUKA-UHFFFAOYSA-N buclosamide Chemical compound CCCCNC(=O)C1=CC=C(Cl)C=C1O ZGJHIFYEQJEUKA-UHFFFAOYSA-N 0.000 description 1
- 229950000430 buclosamide Drugs 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- PEWXRXAGXPYMIB-ANPZCEIESA-L calcium;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Ca+2].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 PEWXRXAGXPYMIB-ANPZCEIESA-L 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229950000776 carbarsone Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 229960000717 carindacillin Drugs 0.000 description 1
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 description 1
- UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 description 1
- 229960000662 carumonam Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- DIGADQKVPFDJSI-SPYBWZPUSA-N cefalexin pivoxil Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DIGADQKVPFDJSI-SPYBWZPUSA-N 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960005312 cefazedone Drugs 0.000 description 1
- VTLCNEGVSVJLDN-MLGOLLRUSA-N cefazedone Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3C=C(Cl)C(=O)C(Cl)=C3)[C@H]2SC1 VTLCNEGVSVJLDN-MLGOLLRUSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001817 cefbuperazone Drugs 0.000 description 1
- SMSRCGPDNDCXFR-CYWZMYCQSA-N cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 description 1
- 229950004627 cefcapene pivoxil Drugs 0.000 description 1
- JUVHVMCKLDZLGN-TVNFHGJBSA-N cefclidin Chemical compound N([C@@H]1C(N2C(=C(C[N+]34CCC(CC3)(CC4)C(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 JUVHVMCKLDZLGN-TVNFHGJBSA-N 0.000 description 1
- 229950011467 cefclidin Drugs 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960004069 cefditoren Drugs 0.000 description 1
- KMIPKYQIOVAHOP-YLGJWRNMSA-N cefditoren Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C KMIPKYQIOVAHOP-YLGJWRNMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-O cefepime(1+) Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-O 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960001958 cefodizime Drugs 0.000 description 1
- XDZKBRJLTGRPSS-BGZQYGJUSA-N cefodizime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- QDUIJCOKQCCXQY-WHJQOFBOSA-N cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 description 1
- 229960002642 cefozopran Drugs 0.000 description 1
- LNZMRLHZGOBKAN-KAWPREARSA-N cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 description 1
- 229950004036 cefpimizole Drugs 0.000 description 1
- 229960005446 cefpiramide Drugs 0.000 description 1
- PWAUCHMQEXVFJR-PMAPCBKXSA-N cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 description 1
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 1
- 229960000466 cefpirome Drugs 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960003844 cefroxadine Drugs 0.000 description 1
- RDMOROXKXONCAL-UEKVPHQBSA-N cefroxadine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)OC)C(O)=O)=CCC=CC1 RDMOROXKXONCAL-UEKVPHQBSA-N 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229950000679 cefteram Drugs 0.000 description 1
- DZMVCVMFETWNIU-LDYMZIIASA-N ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 description 1
- 229960004366 ceftezole Drugs 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 description 1
- 229950000807 cefuzonam Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- DTGZHCFJNDAHEN-OZEXIGSWSA-N cephaeline Chemical compound N1CCC2=CC(O)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC DTGZHCFJNDAHEN-OZEXIGSWSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 description 1
- 229940009063 cephapirin sodium Drugs 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- NPGNOVNWUSPMDP-UTEPHESZSA-N chembl1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- STLZCUYBVPNYED-UHFFFAOYSA-N chlorbetamide Chemical compound OCCN(C(=O)C(Cl)Cl)CC1=CC=C(Cl)C=C1Cl STLZCUYBVPNYED-UHFFFAOYSA-N 0.000 description 1
- 229950008246 chlorbetamide Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960000849 chlormidazole Drugs 0.000 description 1
- WNAQOLSMVPFGTE-UHFFFAOYSA-N chlormidazole Chemical compound CC1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1 WNAQOLSMVPFGTE-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960003801 clefamide Drugs 0.000 description 1
- ODCUSWJXZDHLKV-UHFFFAOYSA-N clefamide Chemical compound C1=CC(CN(CCO)C(=O)C(Cl)Cl)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 ODCUSWJXZDHLKV-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003769 clofoctol Drugs 0.000 description 1
- 229960001351 clometocillin Drugs 0.000 description 1
- JKXQBIZCQJLVOS-GSNLGQFWSA-N clometocillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(OC)C1=CC=C(Cl)C(Cl)=C1 JKXQBIZCQJLVOS-GSNLGQFWSA-N 0.000 description 1
- 229960004094 clomocycline Drugs 0.000 description 1
- BXVOHUQQUBSHLD-XCTBDMBQSA-N clomocycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(=C(/O)NCO)/C(=O)[C@@]4(O)C(=O)C3=C(O)C2=C1O BXVOHUQQUBSHLD-XCTBDMBQSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- CTQMJYWDVABFRZ-UHFFFAOYSA-N cloxiquine Chemical compound C1=CN=C2C(O)=CC=C(Cl)C2=C1 CTQMJYWDVABFRZ-UHFFFAOYSA-N 0.000 description 1
- 229950003660 cloxiquine Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960003807 dibekacin Drugs 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N dibekacin Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229960000493 dibrompropamidine Drugs 0.000 description 1
- GMJFVGRUYJHMCO-UHFFFAOYSA-N dibrompropamidine Chemical compound BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br GMJFVGRUYJHMCO-UHFFFAOYSA-N 0.000 description 1
- 229960004941 difetarsone Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 229950001733 difloxacin Drugs 0.000 description 1
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 229960004462 dimazole Drugs 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WJQJTJQDBFMBJM-UHFFFAOYSA-L disodium;hydroxy-[4-[2-[4-[hydroxy(oxido)arsoryl]anilino]ethylamino]phenyl]arsinate Chemical compound [Na+].[Na+].C1=CC([As]([O-])(=O)O)=CC=C1NCCNC1=CC=C([As](O)([O-])=O)C=C1 WJQJTJQDBFMBJM-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002125 enilconazole Drugs 0.000 description 1
- MIZMDSVSLSIMSC-OGLSAIDSSA-N enniatin Chemical compound CC(C)C1OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C(=O)C(C(C)C)OC(=O)[C@H](C(C)C)N(C)C1=O MIZMDSVSLSIMSC-OGLSAIDSSA-N 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229950000219 enviomycin Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- TYQXKHPOXXXCTP-CSLYCKPJSA-N erythromycin A 2'-propanoate Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 TYQXKHPOXXXCTP-CSLYCKPJSA-N 0.000 description 1
- CVBHEIRZLPKMSH-SNWVVRALSA-N erythromycin acistrate Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 CVBHEIRZLPKMSH-SNWVVRALSA-N 0.000 description 1
- 229950007610 erythromycin acistrate Drugs 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229950001028 erythromycin propionate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229950010333 exalamide Drugs 0.000 description 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- VZPPEUOYDWPUKO-MQWDNKACSA-N fenbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C=1C=CC=CC=1)OC1=CC=CC=C1 VZPPEUOYDWPUKO-MQWDNKACSA-N 0.000 description 1
- 229950002965 fenbenicillin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019374 flavomycin Nutrition 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N flomoxef Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960000702 flumequine Drugs 0.000 description 1
- 229940060037 fluorine Drugs 0.000 description 1
- 229960000690 flutrimazole Drugs 0.000 description 1
- QHMWCHQXCUNUAK-UHFFFAOYSA-N flutrimazole Chemical compound C1=CC(F)=CC=C1C(N1C=NC=C1)(C=1C(=CC=CC=1)F)C1=CC=CC=C1 QHMWCHQXCUNUAK-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000936 fumagillin Drugs 0.000 description 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-M fumagillin(1-) Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C([O-])=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-M 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950000337 furaltadone Drugs 0.000 description 1
- 229950008849 furazolium chloride Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 108010092764 fusafungin Proteins 0.000 description 1
- 229960003847 fusafungine Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- 229950009774 gramicidin s Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229950007488 guamecycline Drugs 0.000 description 1
- 229950005233 haletazole Drugs 0.000 description 1
- TXOKWXJQVFUUDD-UHFFFAOYSA-N haletazole Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C1=NC2=CC(Cl)=CC=C2S1 TXOKWXJQVFUUDD-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- KDOWHHULNTXTNS-UHFFFAOYSA-N hex-3-yne-2,5-diol Chemical compound CC(O)C#CC(C)O KDOWHHULNTXTNS-UHFFFAOYSA-N 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- 229950004575 hexedine Drugs 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- FMPJXUZSXKJUQI-UHFFFAOYSA-N hydron;3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole;chloride Chemical compound Cl.O1C([N+](=O)[O-])=CC=C1C1=CSC2=NCCN12 FMPJXUZSXKJUQI-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960000798 isepamicin Drugs 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 229950010163 lanoconazole Drugs 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- ZKUKMWMSYCIYRD-ZXFNITATSA-N lenampicillin Chemical compound O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3N2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C ZKUKMWMSYCIYRD-ZXFNITATSA-N 0.000 description 1
- 229950005831 lenampicillin Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- ZHNUMLOCJMCLIT-UHFFFAOYSA-N loflucarban Chemical compound C1=CC(F)=CC=C1NC(=S)NC1=CC(Cl)=CC(Cl)=C1 ZHNUMLOCJMCLIT-UHFFFAOYSA-N 0.000 description 1
- 229950002384 loflucarban Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-M loracarbef anion Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)N)=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-M 0.000 description 1
- 229960004196 lymecycline Drugs 0.000 description 1
- AHEVKYYGXVEWNO-UEPZRUIBSA-N lymecycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(=O)NCNCCCC[C@H](N)C(O)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O AHEVKYYGXVEWNO-UEPZRUIBSA-N 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229960000826 meclocycline Drugs 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960004011 methenamine Drugs 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- 229960003412 methenamine sulfosalicylate Drugs 0.000 description 1
- AKWHOGIYEOZALP-UHFFFAOYSA-N methyl 2-methoxy-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC AKWHOGIYEOZALP-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229960004744 micronomicin Drugs 0.000 description 1
- 229950007764 mikamycin Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229950007835 miloxacin Drugs 0.000 description 1
- ABQYZRZVRIPTPI-UHFFFAOYSA-N miloxacin Chemical compound C1=C2N(OC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 ABQYZRZVRIPTPI-UHFFFAOYSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960000931 miocamycin Drugs 0.000 description 1
- GQNZGCARKRHPOH-RQIKCTSVSA-N miocamycin Chemical compound C1[C@](OC(C)=O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C GQNZGCARKRHPOH-RQIKCTSVSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- ARGDYOIRHYLIMT-UHFFFAOYSA-N n,n-dichloro-4-methylbenzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N(Cl)Cl)C=C1 ARGDYOIRHYLIMT-UHFFFAOYSA-N 0.000 description 1
- FBFBRAFXKGRRHI-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyl-4-propan-2-yloxybenzamide Chemical compound C1=CC(OC(C)C)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(N)C=C1 FBFBRAFXKGRRHI-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229950001913 nifuradene Drugs 0.000 description 1
- SRQKTCXJCCHINN-NYYWCZLTSA-N nifuratel Chemical compound O=C1OC(CSC)CN1\N=C\C1=CC=C([N+]([O-])=O)O1 SRQKTCXJCCHINN-NYYWCZLTSA-N 0.000 description 1
- 229960002136 nifuratel Drugs 0.000 description 1
- WCEJYDIWHURKJX-VGOFMYFVSA-N nifurfoline Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)N(CN2CCOCC2)C(=O)C1 WCEJYDIWHURKJX-VGOFMYFVSA-N 0.000 description 1
- 229950000495 nifurfoline Drugs 0.000 description 1
- XDWLRMBWIWKFNC-HNQUOIGGSA-N nifurprazine Chemical compound N1=NC(N)=CC=C1\C=C\C1=CC=C([N+]([O-])=O)O1 XDWLRMBWIWKFNC-HNQUOIGGSA-N 0.000 description 1
- 229950005949 nifurprazine Drugs 0.000 description 1
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
- 229960004918 nimorazole Drugs 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 229960005131 nitroxoline Drugs 0.000 description 1
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 229960004031 omoconazole Drugs 0.000 description 1
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- WVNOAGNOIPTWPT-NDUABGMUSA-N oxiconazole nitrate Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)/CN1C=NC=C1 WVNOAGNOIPTWPT-NDUABGMUSA-N 0.000 description 1
- 229960002894 oxiconazole nitrate Drugs 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229950011346 panipenem Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- NLOOMWLTUVBWAW-HLLBOEOZSA-N penamecillin Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C)C(=O)CC1=CC=CC=C1 NLOOMWLTUVBWAW-HLLBOEOZSA-N 0.000 description 1
- 229960000596 penamecillin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 235000019368 penicillin G potassium Nutrition 0.000 description 1
- 235000019370 penicillin G procaine Nutrition 0.000 description 1
- 229940056365 penicillin g benzathine Drugs 0.000 description 1
- 229940056362 penicillin g procaine Drugs 0.000 description 1
- 229940024772 penicillin v benzathine Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- UQGPCEVQKLOLLM-UHFFFAOYSA-N pentaneperoxoic acid Chemical compound CCCCC(=O)OO UQGPCEVQKLOLLM-UHFFFAOYSA-N 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- BBTOYUUSUQNIIY-ANPZCEIESA-N phenoxymethylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 BBTOYUUSUQNIIY-ANPZCEIESA-N 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- XATZHCXBMKRRDO-REHNUXHNSA-N pipacycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCN(CCO)CC1 XATZHCXBMKRRDO-REHNUXHNSA-N 0.000 description 1
- 229950001465 pipacycline Drugs 0.000 description 1
- 229960001732 pipemidic acid Drugs 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 229960004444 piromidic acid Drugs 0.000 description 1
- RCIMBBZXSXFZBV-UHFFFAOYSA-N piromidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCCC1 RCIMBBZXSXFZBV-UHFFFAOYSA-N 0.000 description 1
- 229960004212 pivmecillinam Drugs 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000980 poly(hydroxybutyrate-co-hydroxyvalerate) Polymers 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 1
- 229950001405 polybenzarsol Drugs 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- ZDHURYWHEBEGHO-UHFFFAOYSA-N potassiopotassium Chemical compound [K].[K] ZDHURYWHEBEGHO-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229950010664 primycin Drugs 0.000 description 1
- NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 description 1
- 229960003961 pristinamycin Drugs 0.000 description 1
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 1
- JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960003672 propicillin Drugs 0.000 description 1
- HOCWPKXKMNXINF-XQERAMJGSA-N propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
- 229950009721 quinacillin Drugs 0.000 description 1
- GPMSLJIYNWBYEL-TYNCELHUSA-N quinacillin Chemical compound C1=CC=C2N=C(C(O)=O)C(C(=O)N[C@H]3[C@H]4SC([C@@H](N4C3=O)C(O)=O)(C)C)=NC2=C1 GPMSLJIYNWBYEL-TYNCELHUSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- SBJGFIXQRZOVTO-UHFFFAOYSA-N quinfamide Chemical compound C=1C=C2N(C(=O)C(Cl)Cl)CCCC2=CC=1OC(=O)C1=CC=CO1 SBJGFIXQRZOVTO-UHFFFAOYSA-N 0.000 description 1
- 229960001628 quinfamide Drugs 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- 229960003485 ribostamycin Drugs 0.000 description 1
- 229930190553 ribostamycin Natural products 0.000 description 1
- NSKGQURZWSPSBC-UHFFFAOYSA-N ribostamycin A Natural products NC1C(O)C(O)C(CN)OC1OC1C(OC2C(C(O)C(CO)O2)O)C(O)C(N)CC1N NSKGQURZWSPSBC-UHFFFAOYSA-N 0.000 description 1
- NSKGQURZWSPSBC-VVPCINPTSA-R ribostamycin(4+) Chemical compound [NH3+][C@@H]1[C@@H](O)[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H]([NH3+])C[C@@H]1[NH3+] NSKGQURZWSPSBC-VVPCINPTSA-R 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229950003104 rifamide Drugs 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- VFYNXKZVOUXHDX-VDPUEHCXSA-N rifamycin b diethylamide Chemical compound CC1=C(O)C(C=2O)=C3C(OCC(=O)N(CC)CC)=CC=2NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]2(C)OC1=C3C2=O VFYNXKZVOUXHDX-VDPUEHCXSA-N 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- 229960003040 rifaximin Drugs 0.000 description 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229950004286 ritipenem Drugs 0.000 description 1
- IKQNRQOUOZJHTR-UWBRJAPDSA-N ritipenem Chemical compound S1C(COC(N)=O)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 IKQNRQOUOZJHTR-UWBRJAPDSA-N 0.000 description 1
- 229960001170 rokitamycin Drugs 0.000 description 1
- 229960005009 rolitetracycline Drugs 0.000 description 1
- HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
- IUPCWCLVECYZRV-JZMZINANSA-N rosaramicin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H]([C@@H]2O[C@@]2(C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O IUPCWCLVECYZRV-JZMZINANSA-N 0.000 description 1
- 229950001447 rosaramicin Drugs 0.000 description 1
- 229960003889 rosoxacin Drugs 0.000 description 1
- XBPZXDSZHPDXQU-UHFFFAOYSA-N rosoxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=C1C1=CC=NC=C1 XBPZXDSZHPDXQU-UHFFFAOYSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960004062 rufloxacin Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229950000614 sancycline Drugs 0.000 description 1
- 229950005137 saperconazole Drugs 0.000 description 1
- 229960005429 sertaconazole Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- CBXWGGFGZDVPNV-UHFFFAOYSA-N so4-so4 Chemical compound OS(O)(=O)=O.OS(O)(=O)=O CBXWGGFGZDVPNV-UHFFFAOYSA-N 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002999 sulbentine Drugs 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- WVAKABMNNSMCDK-UHFFFAOYSA-N sulfacarbamide Chemical compound NC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 WVAKABMNNSMCDK-UHFFFAOYSA-N 0.000 description 1
- 229950010053 sulfacarbamide Drugs 0.000 description 1
- 229960002076 sulfacytine Drugs 0.000 description 1
- SIBQAECNSSQUOD-UHFFFAOYSA-N sulfacytine Chemical compound O=C1N(CC)C=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 SIBQAECNSSQUOD-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- BRBKOPJOKNSWSG-UHFFFAOYSA-N sulfaguanidine Chemical compound NC(=N)NS(=O)(=O)C1=CC=C(N)C=C1 BRBKOPJOKNSWSG-UHFFFAOYSA-N 0.000 description 1
- 229960004257 sulfaguanidine Drugs 0.000 description 1
- 229950004215 sulfanitran Drugs 0.000 description 1
- 229960000277 sulfaperin Drugs 0.000 description 1
- DZQVFHSCSRACSX-UHFFFAOYSA-N sulfaperin Chemical compound N1=CC(C)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 DZQVFHSCSRACSX-UHFFFAOYSA-N 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229950001296 sulfaproxyline Drugs 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- AKHFYKDNVOFEMG-UHFFFAOYSA-N sulfarside Chemical compound NC1=CC(S(N)(=O)=O)=CC=C1[As](O)(O)=O AKHFYKDNVOFEMG-UHFFFAOYSA-N 0.000 description 1
- 229950006894 sulfarside Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- JVYKJZPZFIUYAB-UHFFFAOYSA-N sulfasomizole Chemical compound S1N=C(C)C=C1NS(=O)(=O)C1=CC=C(N)C=C1 JVYKJZPZFIUYAB-UHFFFAOYSA-N 0.000 description 1
- 229950001997 sulfasomizole Drugs 0.000 description 1
- ZQMQGBHQZZQTJE-UHFFFAOYSA-N sulfasymazine Chemical compound CCC1=NC(CC)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZQMQGBHQZZQTJE-UHFFFAOYSA-N 0.000 description 1
- 229950003748 sulfasymazine Drugs 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960003356 sulfatolamide Drugs 0.000 description 1
- 229960001975 sulfisomidine Drugs 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
- 229960004267 taurolidine Drugs 0.000 description 1
- 229960002299 teclozan Drugs 0.000 description 1
- MSJLJWCAEPENBL-UHFFFAOYSA-N teclozan Chemical compound CCOCCN(C(=O)C(Cl)Cl)CC1=CC=C(CN(CCOCC)C(=O)C(Cl)Cl)C=C1 MSJLJWCAEPENBL-UHFFFAOYSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 229960001114 temocillin Drugs 0.000 description 1
- BVCKFLJARNKCSS-DWPRYXJFSA-N temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 description 1
- 229960004480 tenonitrozole Drugs 0.000 description 1
- ZLOXYEZYWCTXHU-UHFFFAOYSA-N tenonitrozole Chemical compound S1C([N+](=O)[O-])=CN=C1NC(=O)C1=CC=CS1 ZLOXYEZYWCTXHU-UHFFFAOYSA-N 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
- KVEZIRCKNOTGKY-UHFFFAOYSA-N thiazosulfone Chemical compound S1C(N)=NC=C1S(=O)(=O)C1=CC=C(N)C=C1 KVEZIRCKNOTGKY-UHFFFAOYSA-N 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229940063214 thiostrepton Drugs 0.000 description 1
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 1
- 229930188070 thiostrepton Natural products 0.000 description 1
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N tigemonam Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 description 1
- 229950010206 tigemonam Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229950007633 tolindate Drugs 0.000 description 1
- ANJNOJFLVNXCHT-UHFFFAOYSA-N tolindate Chemical compound C=1C=C2CCCC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 ANJNOJFLVNXCHT-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229950000976 trospectomycin Drugs 0.000 description 1
- KHAUBYTYGDOYRU-IRXASZMISA-N trospectomycin Chemical compound CN[C@H]([C@H]1O2)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]1O[C@H]1[C@]2(O)C(=O)C[C@@H](CCCC)O1 KHAUBYTYGDOYRU-IRXASZMISA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 108700030422 tuberactinomycin Proteins 0.000 description 1
- SZCZSKMCTGEJKI-UHFFFAOYSA-N tuberin Natural products COC1=CC=C(C=CNC=O)C=C1 SZCZSKMCTGEJKI-UHFFFAOYSA-N 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- AFOTXNKRSJVXBS-UHFFFAOYSA-N uropurat Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O AFOTXNKRSJVXBS-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- HLDCSYXMVXILQC-UHFFFAOYSA-N xenysalate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1O HLDCSYXMVXILQC-UHFFFAOYSA-N 0.000 description 1
- 229960003434 xenysalate Drugs 0.000 description 1
- LFAXYIHYMGEIHW-UHFFFAOYSA-N xyloylsulfamine Chemical compound C1=C(C)C(C)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(N)C=C1 LFAXYIHYMGEIHW-UHFFFAOYSA-N 0.000 description 1
- XSMMCTCMFDWXIX-UHFFFAOYSA-N zinc silicate Chemical compound [Zn+2].[O-][Si]([O-])=O XSMMCTCMFDWXIX-UHFFFAOYSA-N 0.000 description 1
- 235000019352 zinc silicate Nutrition 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
- A61L24/0089—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
- A61F2002/30064—Coating or prosthesis-covering structure made of biodegradable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/3011—Cross-sections or two-dimensional shapes
- A61F2002/30112—Rounded shapes, e.g. with rounded corners
- A61F2002/30113—Rounded shapes, e.g. with rounded corners circular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/3011—Cross-sections or two-dimensional shapes
- A61F2002/30138—Convex polygonal shapes
- A61F2002/30153—Convex polygonal shapes rectangular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30108—Shapes
- A61F2002/30199—Three-dimensional shapes
- A61F2002/30291—Three-dimensional shapes spirally-coiled, i.e. having a 2D spiral cross-section
- A61F2002/30293—Cylindrical body made by spirally rolling up a sheet or a strip around itself
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30667—Features concerning an interaction with the environment or a particular use of the prosthesis
- A61F2002/30677—Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/30769—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth madreporic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
- A61F2002/30772—Apertures or holes, e.g. of circular cross section
- A61F2002/30784—Plurality of holes
- A61F2002/30785—Plurality of holes parallel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/30971—Laminates, i.e. layered products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0006—Rounded shapes, e.g. with rounded corners circular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0017—Angular shapes
- A61F2230/0019—Angular shapes rectangular
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0091—Three-dimensional shapes helically-coiled or spirally-coiled, i.e. having a 2-D spiral cross-section
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00592—Coating or prosthesis-covering structure made of ceramics or of ceramic-like compounds
- A61F2310/00796—Coating or prosthesis-covering structure made of a phosphorus-containing compound, e.g. hydroxy(l)apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicinal Chemistry (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Description
1374036 (1) 九、發明說明 【發明所屬之技術領域】 本發明包括包含至少一層聚合物層與至少一層含鈣層 之可撓性骨複合材料,及彼之製造方法。本發明之複合材 料具有經改良之操作特徵。 【·先前技術】 | 與骨水泥(bone cement)或磷酸組成物有關之重要 領域的焦點集中在以各種材料強化骨水泥。通常陶瓷骨水 泥雖然夠強健但易碎,且無法充分耐嚴重損壞(例如裂穿 )’而無法作爲基質材料。聚合物可用於強化陶瓷骨組份 。例如,已習知包含添加有強化塡充粒子、鬚或網的強健 , . · 且具回彈性之基質的可植入複合材料。與例如習用非可再 吸收金屬或複合材料相較,諸如聚乳交醋與聚乙交酯等可 再吸收植入材料具有生物相容性、於—段時間後之可生物 |分解性’以及在例如骨固定或修復應用中不需要移除等優 點。此等特質可用於植入設計爲例如骨空腔或缺損之復原 及/或再生長用的暫時性置入塡充物(在某些情況下,作 爲穩定組件)。 【發明內容】 本發明包括可撓性骨複合材料,其包括至少一層聚合 物層與至少一層含鈣層。 在一具體實施例中,該可撓性骨複合材料包括:(a -5- (2) 1374036 )一聚合物層,其具有第一面與第二面;及(b) 一第— 含鈣層’其係固定或物理性及/或化學性貼附於該聚合物 層之第一面。 在另一具體實施例中,該可撓性骨複合材料包括:( a) ~經衝孔之聚合物層’其具有第—面與第二面;以及 (b ) —含鈣層,其係固定或物理性及/或化學性貼附於 該聚合物層之第一面。 .本發明亦包括用於製造包括至少一層聚合物層與至少 一層含鈣層之可撓性骨複合材料的方法。 在一具體實施例中’本發明包括用於製造包括具有第 一面與第二面之聚合物層之可撓性骨複合材料的方法,其 包括:將一鈣化合物置於該聚合物層的第一面,以形成第 一含釣層。 在另一具體實施例中,本發明包括用於製造包括具有 第一面與第二面之聚合物層之可撓性骨複合材料的方法, φ其包括:使第一鈣化合物與該聚合物層的第一面接觸,以 形成第一中間產物複合材料;並在足以使該第一銘化合物 固定或物理性及/或化學性貼附於該聚舍物層的第—面之 溫度下加熱該第一中間產物複合材料,提供第一含釣層。. 在另一具體實施例中’本發明包括用以製造包括具有 第一面與第二面之聚合物層之可撓性骨複合材料的方法, 其包括:將含鈣層該聚合物與溶劑的溶液澆鑄於一脫模表 面(release surface );使該溶液膠凝;使該鈣化合物與 該凝膠的第一面接觸;並使該溶劑自凝膠蒸發,形成具有 -6- ' (3) 1374036 ' 固定或物理性及/或化學性貼附於該聚合物層第一面的第 一含鈣層之可撓性骨複合材料。 在另一具體實施例中,本發明包括用於製造包括具有 . 第—面與第二面之經衝孔聚合物層之可撓性骨複合材料的 方法’其包括:對一聚合物層衝孔,形成經衝孔聚合物層 :加熱該經衝孔聚合物層;使該第一鈣化合物與該經衝孔 聚合物膜的第一面接觸,形成第一中間產物複合材料;並 φ 使該第—中間產物複合材料冷卻至足以使該第一鈣化合物 固定或物理性及/或化學性貼附於該經衝孔聚合物層第一 面的溫度,提供一含鈣層。 在另一具體實施例中,本發明包括用以對有需要之病 患治療硬組織缺損的方法。 在另一具體實施例中,本發明包括包括用以對有需要 •之病患治療骨骼缺損的方法,包括:將一治療有效量之包 括至少—層聚合物層與至少一層鈣化合物的可撓性骨複合 %材料植入該缺損。 在另一具體實施例中’本發明包括一可撓性骨水泥組 • 成物’其可經模塑以塡充空腔’諸如例如骨空腔,以及此 等組成物的製造方法。在另高具體實施例中,本發明包括 植入用之含可撓性複合材料’由於其成份性質的特定組 合’其在主要機械性質有所改浪❶ 另一具體實施例中’本發明亦包括套組,其包括—含 有一包括至少一層聚合物層與至少一層含鈣層的可撓性骨 複合材料之外罩。
-7- (4) 1374036 ^ 本發明細節係詳述於下文之附隨說明與實例中。雖然 可使用任何與本文所述相似或相當的方法與材料進行或試 驗本發明’但現在茲描述例證方法與材料。由本文說明及 申請專利範圍可明白本發明其他特性、目的及優點。在本 說明書及隨附之申請專利範圍中’除非原文內容另有明確 指定,否則單數形亦包括複數形。 ^ 【實施方式】 如目I』述’本發明包括具有至少一層聚合物層與至少一 層含鈣層的可撓性骨複合材料。通常,該至少=層聚合物 層具有第一面與第二面’且該至少一層含鈣層至少位於該 至少一層聚合物層的第一面上。 該聚合物層包括一種聚合物。該聚合物可爲可再吸收 聚合物、非可再吸收聚合物或其組合。在一具體實施例中 ,相對於該聚合物層總重,該聚合物層包含低於約i 0重 0量%之非可再吸收聚合物,較佳係低於約5重量%之非可 . 再吸收聚合物,更佳係低於約1重量%之非可再吸收聚合 物。 在一較佳具體實施例中’該聚合物層包括一可再吸收 聚合物’且該聚合物層基本上沒有非可再吸收聚合物。較 佳情況係,該可再吸收聚合物層係體內可再吸收,且包括 —可再吸收聚合物。 該聚合物層中之聚合物可包括合成聚合物、非合成聚 合物(即’由植物或動物製得之聚合物),或其組合。在 -8- 1374036 一具體實施例中,該聚合物層包括合成聚合物,且該聚合 物層基本上沒有非合成聚合物。例如,相對於該聚合物層 總重,該聚合物層可含有低於約1〇重量%之非合成聚合 物,較佳係低於約5重量%之非合成聚合物,更佳係低於 約1重量%之非合成聚合物。 在一具體實施例中,該可撓性骨複合材料包括一包含 合成聚合物的聚合物層與一含鈣層。 | 在另一具體實施例中,該可撓性骨複合材料包括:( a) —包括合成聚合物的聚合物層,其中該聚合物層基本 上沒有非合成聚合物;以及(b) —含鈣層。須暸解,本 文所使用之「基本上沒有」一辭意指存在低於約〇. 5重量 %該基本上沒有的組份,較佳係低於約0.2重量%,更佳 係低於約〇. 1重量%,且通常是不存在此種組份。 在其他具體實施例中,該可撓性骨複合材料包括:( a) —聚合物層,其包括合成聚合物,其中該聚合物層實 φ質上沒有非合成聚合物,且實質上沒有非可再吸收聚合物 ;及(1〇 —含錦層。 在一具體實施例中,該可撓性骨複合材料包括:·(a )一可再吸收聚合物層,其包括合成聚合物,且具有第一 面與第二面;以及(b )固定或物理性及/或化學性貼附 於該可再吸收聚合物層的第一面之第一含鈣層。 本文所使用之「聚合物」一辭包括均聚物與共聚物( 即,包括兩種或以上不同單體單元的聚合物)。本文所使 用之「共聚物」一辭包括但不局限於更迭共聚物、無規共 -9- 1374036
I I Λ (6) * 聚物、嵌段共聚物或其任何組合。 在一具體實施例中,相對於該聚合物層總重,該聚合 物層含有低於約25重量%之含鈣化合物。在另一具體實 施例中,相對於該聚合物層總重,該聚合物層含有低於約 10重量%之鈣化合物。在另一具體實施例中,相對於該 聚合物層總重,該聚合物層含有低於約1重量%之鈣化合 物。較佳情況係,該聚合物層基本上沒有鈣化合物。 φ 適於製備該聚合物層的聚合物實例包括但不局限於選 自下列各者之單體的均聚物或共聚物:L -乳交·酯;L -乳酸;D —乳交酯;D —乳酸;乙交酯;α —羥基丁酸; α —羥基戊酸:α —羥基醋酸;《-羥基己酸;α —羥基 庚酸;ct —羥基癸酸;α —羥基肉豆蔻酸;ά —羥基辛酸 ;α-羥基硬脂酸;羥基丁酸酯;羥基戊酸酯;丙交 酯(/S-propiolactide);沒一丙乳酸;7-己內酯;/5-己內酯;ε_己內酯;丁內酯;新戊內酯;四甲基乙 φ交醋:四甲基羥基乙酸;二甲基羥基乙酸;碳酸丙二酯; - 二氧雜環己酮;形成液晶聚合物之單體;形成纖維素之單 . 體;形成醋酸纖維素之單體;形成羧甲基纖維素之單體; 形成羥基丙甲基纖維素之單體;聚胺基甲酸酯前驅體,包 括選自聚己內酯、聚(環氧乙烷)、聚(乙二醇)、聚( 己二酸乙二酯)、聚(環氧丁烷)及其混合物的巨二醇類 、選自二異氰酸己二酯' 二異氰酸異佛爾酮酯、二異氰酸 環己烷酯、經氫化亞甲基二伸苯基二異氰酸酯及其混合物 的異氰酸酯官能化合物、以及選自乙二胺、1,4一 丁二醇 -10- 1374036 卜 (7) ‘、1,2 — 丁二醇、2 —胺基一 1— 丁醇、硫代二甘醇、2_ 锍基乙基醚、3_己炔—2,5 —二醇、檸檬酸及其混合物 的鏈增長劑,以及前述二者或二者以上的任何組合。 在一具體實施例中,該聚合物層包括可再吸收聚合物 。可再吸收聚合物的非限制性實例包括例如衍生自下列單 體的聚合物:L —乳酸、D_乳酸、L -乳交酯、D-乳交 醋、D’ L —乳交醋、乙交醋、內醋、內酿胺、ε _己內 _ 酯、碳酸丙二酯、環碳酸酯、環醚、對二氧雜環己酮、冷 一羥基丁酸、/5 -羥基丙酸、沒-羥基戊酸、糖類、膠原 蛋白、纖維蛋白、清蛋白及前述二者或二者以上之任何組 合。 在另—具體實施例中’該聚合物層包括可再吸收合成 聚合物。可再吸收合成聚合物的非限制性實例包括例如聚 (L 一乳交酯)(共)聚合物、聚(D,L —乳交醋)(共 )聚合物、聚乙交酯(共)聚合物 '聚己內醋(共)聚合 φ物、聚(四甲基羥基乙酸)(共)聚合物、聚二氧雜環己 酮(共)聚合物、聚羥基丁酸酯(共)聚合物、聚羥基戊 酸酯(共)聚合物、聚(L-乳交酯一共聚一乙交醋)共 聚物、聚(乙交酯一共聚一碳酸丙二酯)共聚物、聚(乙 父醋一共聚一己內醋)共聚物、聚(乙交酯—共聚—二氧 雜環己酮一共聚-碳酸丙二酯)共聚物、聚(四甲基經基 乙酸一共聚一二氧雜環己酮_共聚一碳酸丙二_)共聚物 、聚(乙交酯—共聚一己內酯一共聚一L一乳交醋一共聚 〜碳酸丙二酯)共聚物、聚(乳交酯一共聚一己內酯)共 -11 - (8) !374〇36 聚物、聚(羥基丁酸酯-共聚羥基戊酸酯)共聚物、液晶 (共)聚合物、其組合,或其共聚物。 在一具體實施例中,該聚合物層包括聚(L 一乳交酯 〜共聚一乙交酯)共聚物。 在另一具體實施例中,該聚合物層包括選自L-乳交 酯、D —乳交酯、d,L —乳交酯、ε —己內酯 '碳酸丙二 酯、對二氧雜環己酮及前述二者或二者以上之任何組合。 % 在另一具體實施例中,該聚合物層包括L-乳交酯與 ε —己內酯之共聚物。 在另一具體實施例中,該聚合物層包括70%之L -乳 交酯與30% ε -己內酯的共聚物(例如70 : 30聚(L一 乳交酯一共聚—ε —己內酯))。 在一具體實施例中,該聚(L -乳交酯-共聚-ε-乙內酯)共聚物包括至少約15%之乙交酯重複單位與至 少約】5%之L-乳酸重複單位。在另一具體賓施.例中,該 %聚(L —乳交酯一共聚_ e —乙內酯)共聚物包括約82% • 之乙交酯重複單位與約18%之L -乳酸重複單位。在另一 • 具體實施例中’該聚(L —乳交酯_共聚一 £ —乙內酯) 共聚物包括約18%之乙交酯重複單位與約82%之l—乳 酸重複單位。 在另一具體實施例中,該聚合物層包括非可再吸收聚 $物1 °非可再吸收聚合物的非限制性實例包括例如聚乙烯 、聚丙烯與聚胺基甲酸醋。 該聚合物層可購得或使用任何適用之方法,藉由聚合 -12- (9) 1374036 « 各種種類單體(例如L-乳交酯、乙交酯)製得,此等適 用方法係諸如下文所述。當該聚合物層包括兩種或以上不 同單體時(即,爲一種共聚物),使用形成的共聚物生物 分解性或可再吸收性與該機械性質(例如於植入前與植人 期間)符合使用該共聚物之應用需求的任何方法。例如, 美國專利6,096,8 5 5號中發現一種此等聚合方法,該案全 文係以提及的方式併入本文中。用於製造聚(D,L -乳 φ 交酯-共聚-乙交酯)與其他無規共聚物之共聚方法實例 係揭示於美國專利4,1 57,437號,及國際申請案 WO 9 7/3 65 5 3號,此等專利案全文係以提及的方式倂入本 文中。 ' ' 較佳情況下,在一具體實施例中,形成該聚合物層的 聚合物必須具有充分分子量以在所需應用中發揮作用(例 如,機械性能)。通常,聚合實質上全部(即,較佳係至 少約98莫耳%、更佳係至少約99莫耳%,最佳係至少約 φ 99.5莫耳% )該單體及/或二聚物共聚物取代基,可獲得 - 充分高分子量。須暸解本文使用之「分子量」意指聚合程 _ 度、該共聚物鏈中之單體或二聚單位的數量或重量平均數 。本文所使用之分子量可以許多習知方法槪算.,例如諸如 藉由凝膠滲透或尺寸排阻層析術(GPC或SEC )、藉由特 性黏度分析(I.V.)或藉由可求得用以估算共聚物分子量 相關科學技術。 在一具體實施例中,以聚苯乙烯爲標準之GPC或 SEC測量時,本發明的聚合物(於處理或製成膜之前)顯 -13- (10) 1374036 鷂 示出至少約75,000克/莫耳的數量平均分子量,例如自 約150,000克/吴耳至約],〇〇〇, 〇〇〇克/莫耳,或自約 250,000克/旲耳至約900, 〇〇〇克/莫耳。在另—具體實 施例中’此等測量亦獲得至少約125,000克/莫耳的重量 平均分子量,例如至少約250,000克/莫耳或自約 400,000克/莫耳至約2,50〇,〇〇〇克/莫耳。或者,在某 些具體實施例中’該數量平均分子量介於約〗6,0 〇〇克/ φ 莫耳與約75,〇〇〇克/莫耳間,或介於約1 8,000克/莫耳 與約5 0,000克/莫耳間,而該數量平均分子量可介於約 50,000克/莫耳與約150,〇〇〇克/莫耳間,或介於6〇〇〇〇 克/莫耳與約120,000克/莫耳間。 在另一具體實施例中,此等測量亦顯示出多分散性( 即,重量平均分子量對數量平均分子量的比).自約1.3至 約3.5 ’例如自約1.6至約2 · 8,或自約1 . 8 5至約2.· 5。使 用該聚合物層的所需應用通常必須決定分子量値的可接受 φ範圍,例如用於經強化的生物分解性或可再吸收性爲主的 -藥物輸送、顎面植入或其他應用的共聚物顯示在上述範圍 .較低區域甚至低於該範圍的數量平均及/或重量平均分子 量爲佳’然而用於栓、桿、錨、固定釘或其他機械密集及 /或負重應用的共聚物顯示在上述範圍中間或較高區域, 甚或高於該範圍的數量平均及/或重量平均分子量爲佳β 在氯仿中以約0.】% w/ν濃度測量I.V.時,在一具 體實施例中,本發明聚合物(於處理或製成層之前)顯示 出至少約1 ·〇 dl/ g之固有黏度,例如自約2.5 dl/ g至約 -14- (11) 1374036 * 龜 8 dl/g,自約3 d】/g至約7 d】/g,或自約4 dl/g至約 6·5 d】/ g。在另一具體實施例中,本發明之聚(L一乳交 酯一共聚一乙交酯)共聚物可大於約4.5 dl/g。使用該 等聚合物的所需應用通常必須決定特性黏度的可接受範圍 ’例如用於經強化的生物分解性或可再吸收性爲主的藥物 輸送、顎面値入或其他應用的共聚物顯示低於該範圍的特 性黏度爲佳’然而用於栓、桿、錨' 固定釘或其他機械密 ^ 集及/或負重應用的複合材料之膜顯示在上述範圍內甚或 高於該範圍的固有或特性黏度爲佳。 該聚合物可具有低濕氣(或水)含量(即,與該含耗 化合物組份結合之前),例如,不高於約〗.5重量%或不 咼於約1重量%。在一具體實施例中,該濕氣或水含量可 能不高於約5 00 ppm,例如不高於約250 ppm或不高於約 150 ppm。在另一具體實施例中,本發明聚合物的濕氣或 水含量可不高於約200 ppm或不高於約1〇〇 ppm。 φ 在某些具體實施例中,可對該聚合物進行乾燥及/或 • 揮發性有機化合物(VOC )去除步驟,以去除可能存在該 . 聚合物中的水、有機溶劑、未反應單體/二聚物或其他分 子量及/或揮發性雜質或化合物》該乾燥/去除步驟可包 括但不局限於導入較乾燥惰性氣體(例如,諸如乾燥氮、 氬等,其包含此種氣體的混合物)、施加真空(例如,該 壓力不大於約托耳,例如不大於約5托耳或不大於約 1托耳)、施加闻溫(例如’至少約5 0 °C,例如革少約 65°C,諸如自約70°C至約120°C,亦較佳情況下,在該共 (12) 1374036 聚物係至少部分結晶之先決條件下,該高溫不得高於比其 熔融溫度低約5 °C的溫度,例如不得高於比其熔融溫度低 約1 0 °C的溫度)或其任何組合。該乾燥/去除步驟通常 係進行一段充分時間使該濕氣含量在可接受或較佳限制內 。於進行該步驟時,該步驟較佳可包括施加高溫與施加真 空的組合,並進行至少約4小時,例如至少約12小時, 或者不超過24小時,或自約1 6小時至約20小時。 | 該聚合物可顯示出結晶度範圍,較佳値係視欲使用彼 之所需應用而定。在一具體實施例中,該聚合物層係半結 晶,且顯示出自約1 5 %至約30%之結晶度,例如自約20 %至約30%,或例如自約20%至約26%。在另一具體實 施例中,本發明之層可顯示出低於約15%的結晶度。在 另一具體實施例中,本發明之層可顯示出自約15%至約 ’ 50%之結晶度。在其他具體實施例中,本發明之層可顯示 低於約1 0 %、低於約5 %、低於約1%之結晶度,或者可 φ顯示實質上無結晶(即,低於約0.5 %,較佳係低於約 〇· 1 %,或以一或多種實驗方法無法定量偵測的任何結晶 度)。「結晶度」可以許多已詳知之實驗技術測量,且用 於本文時,其係藉由該膜之結晶區與非結晶或非晶相區比 較體積、斷面面積、或通過樣本的線性路行反映出相對比 例。用以測量結晶度之適用實驗技術包括但不局限於差示 掃描量熱法(D S C ) 、X射線散射或繞射法(例如XRD、. WARD ' WAXS等)之類技術。 該聚合物亦顯示出廣泛之完美結晶度(或不完美結晶 -16- (13) 1374036 參 虔)範圍’同樣地’其較佳値係視使用彼等之所需應用而 定。可以藉由例如DSC或其他已詳知(本文中稱爲熔化 熱(△ ( Hf ))實驗技術測量該完美結晶度或不完美結晶 度’其以熔融、或再結晶該共聚物結晶所需的每單位材料 能量(例如,每克焦耳,J/ g ’或每毫克之毫焦耳,mJ/ mg)表示該共聚物的結晶相對完美或不完美。在一具體 實施例中,本發明膜係半結晶,且顯示出低於約5 0 J / g φ 的熔化熱,例如低於約30 J/ g,或低於約25 J/ g。在其 他具體實施例中,本發明膜可顯示出自約50 g至約70 J/g的熔化熱。在另一具體實施例中,本發明膜可顯示 出自約0.5 J/g至約0.15 J/g,自約0.1 J/g至約1〇 J /g,自約〗5 J/g至約25 J/g的熔化熱,或基本上不會 顯示出熔化熱(即’低於約0.1 J/g或以一或多種實聲方 法無法定量偵測的任何比率)。 該聚合物的熔融溫度與玻璃轉化溫度亦會改變,較佳 Φ値視使用彼等的所需應用而定。熔融與玻璃轉化溫度可藉 由例如D S C或其他已詳知之實驗技術測量,且通常與升 溫或降溫的速率有關。標準DSC試驗係以約5 °C /分鐘至 約20°C/分鐘之速率改變溫度,特別是約10°C /分鐘。 以標準DSC試驗測量,在一具體實施例中,本發明聚合 物層的熔融溫度介於約9 0 °C與約2 2 5 °C,例如自約1 I 0 °C 至約I65°C,或自約]30°C至約150°C。在另一具體實施 例中,以D SC試驗測得之該聚合物玻璃轉化溫度介於約 3(TC與約l〇〇°C,例如介於約40°C與約60°C。 -17- (14) 1374036 該聚合物的各種機械性質數値可以廣泛地改變,特別 係視使用彼等之所需應用及將彼等形成該應用所需之物件 或裝置的方法而定。例如’在一具體實施例中,該聚合物 的拉張強度係自約10至約100 MPa。在另一具體實施例 中,該聚合物的彈性模數可自約0.〗至約6 GPa» 當該聚合物及/或組成物用於植入或體內應用時,需 要消毒此等聚合物及/或複合材料,使體內反應^-一例如 φ 感染、異物排斥等等--最小化。由於本發明的可再吸收 聚合物係於存有水中可再吸收或降解,以壓熱處理以外之 消毒方法特別適宜。此種消毒方法可包括但不局限於曝露 於環氧乙烷、曝露於r -輻射、曝露於電子束源、曝露於 冷(或至少低溫)電漿源或其組合方法〇視曝露劑量與曝 露期間而定,該消毒方法爲引發該聚合物支化、接枝或交 聯的可能方式。 在一具體實施例中,可以此等消毒方法的單一或多重 φ劑量對本發明之聚合物、物件或裝置進行.消毒,其量係足 以避免、抑制或減少體內反應。在—較佳具體實施例中, 該消毒作用包括單一劑量於輻射或環氧乙烷。.在另一較佳 具體實施例中,該消毒作用包括使該聚(L一乳交酯一共 聚一ε -己內醋)共聚物或複合材料單—劑量地曝露於約 25 kGy的r —輻射》 當該可再吸收聚合物層包括可再吸收聚合物時,該包 含彼的可燒性骨複合材料可能在約〗個月至約2 5年內顯 不出完全的體內或體外再吸收,例如自約2個月至約2年
18- (15) 1374036 。本文所使用的「完全再吸收」係指以肉眼觀察時,植入 位置沒有明顯物材料’或是分析植入位置之樣本的降 解聚合物時’不存在該聚合物降解所形成數量平均分子量 大於約1,000克/莫耳或不大於約500克/莫耳之寡聚材 料的情況。在其他具體實施例中,在植入體內之後或曝露 於溫度約3 7 °C (· ± 1 °c )且pH値約7 · 4 ( ±0.2 )的磷酸鹽 緩衝鹽水(PBS )溶液之後,本發明的聚合物及/或組成 φ 物一般應保有至少一部分其機械性質。 該聚合物層可由本技術中習知之方法製備。例如,在 —具體實施例中’該聚合物層可使用習用黏彈性液體成型 或液體固定方法製備’該等方法包括但不局限於擠出、壓 縮成型、射出成型、熱成型 '吹模、旋轉成型 '壓延與澆 财(詳見例如 Joel R. Fried 者之 /*〇 /少讲"iSc/e«c:e ,第 373-384 頁(】995 ),與 K.J. Mackenzie 著之 Kirk Oth mer: Encyclopedia of Chemical _ 中 7 75-78 7 頁的"Film and Sheeting Materials (1 993 ) ’前述參考資料全體內容係以提及的方式倂入 . 本文中)。 例如’在其他具體實施例中’該聚合物層可以壓縮成 型或壓延法製備。 在一具體實施例中’該聚合物層係呈薄膜形式。 可改變該聚合物層的數量與厚度。通常,該聚合物層 的存在量係足以提供該含鈣層一可撓性平台。在一具體實 施例中,相對於該可撓性骨複合材料總量,該聚合物層的 -19- (16) 1374036 肇 存在量自約1重量%至約99重量%。在另—具體實施例 中’相對於該可撓性骨複合材料總量,該聚合物層的自約 】〇重量%至約75重量%。在另—具體實施例中’相對於 該可撓性骨複合材料總量,該聚合物層的存在量自約25 重量%至約30重量% ^ 該聚合物層可爲任何適用厚度。例如,該聚合物層的 厚度自約〇_〇1 mm至約ι·〇 mm。在—具體實施例中,該 ^ 聚合物層的厚度自約0.05 mm至約0.5 mm。在另一具體 實施例中,該聚合物層的厚度自約〇.〇5 mm至約0.25 mm 。在較佳具體實施例中,該聚合物層的厚度自約0.05 mm 至約 0.1 5 m m。’ 在一具體實施例中,該聚合物層係有一或多個衝孔。 此等孔可爲該液體提.供穿透該聚合物層的路徑。該等孔可 爲任何大小與形狀,且分布成任何圖案。例如,在某些具 體實施例中,該等孔可以均勻分布在該聚合物層上。當對 φ該聚合物層衝孔時,在一具體實施例中,相對於該聚合物 . 層第一或第二面的總表面積,該衝孔程度自約1面積%至 約90面積% ;在另一具體實施例中,相對於該聚合物層 第一或第二面的總表面積,該衝孔程度自約5面積%至約 7 5面積% ;在另一具體實施例中,相對於該聚合物層第 —或第二面的總表面積,該衝孔程度自約15面積%至約 50面積%。在一較佳具體實施例中’相對於該聚合物層 第一或第二層的總表面積,該衝孔程度約22面積%。 對該聚合物層衝孔的方法包括但不局限於使用衝床、 -20- (17) 1374036 衝模、壓延滾筒衝出穿過該聚合物層的孔,或以刀或柳葉 刀縱割該聚合物層。 該經衝孔層中的孔直徑可變動或可在預定容許値內。 在一具體實施例中,該等孔直徑自約〇.4 mm至約6.5 mm ;在另一具體實施例中,該等孔直徑自約0.8mm至約3.5 mm;在另一具體實施例中,該等孔直徑自約1.0 mm至約 2 mm。在一較佳具體實施例中,該等孔直徑係約1.5 mm 在特定具體實施例中,當該聚合物層係以刀或柳葉刀 切割衝孔時,該切口或或隙縫的長度可變動。在一具體實 施例中,該切口長度自約0.5至約10 mm;在另一具體實 施例中,該切口長度自約1至約5 mm ;在另一具體實施 例中,該切口長度自約2至約3mn^ 在一具體實施例中,本發明包括一可撓性骨複合材料 ,其包括:(a )具有第一面與第二面之經衝孔聚合物層 φ :及(b )固定或物理性及/或化學性貼附於該聚合物層 之第一面的第一含鈣層。在另一具體實施例中,本發明包 括一可撓性骨複合材料,其包括:(a)具有第一面與第 二面的經衝孔可再吸收聚合物層;及(b )固定或物理性 及/或化學性貼附於該可再吸收聚合物層第一面的第一含 鈣層。 在另一具體實施例中,該可撓性骨複合材料包括第二 可再吸收聚合物層。在其他具體實施例中,該第二可再吸 收聚合物層可固定或物理性及/或化學性貼附於該聚合物 -21 - (18) 1374036 層的第二面或該含鈣層。適於製造該第二聚合物層之聚合 物層的非限制性實例包括前文討論供該聚合物層用的均聚 物或共聚物。 在一具體實施例中,該第二聚合物層係可再吸收,且 包括一合成聚合物。 在另一具體實施例中,該第二聚合物層係經衝孔,如 前述該聚合物層。 | 在另一具體實施例中,該第二可再吸收聚合物層未經 衝孔。該第二聚合物層的厚度可爲任何適用厚度,如前述 該聚合物層。在一具體實施例中,該聚合物層與該第二聚 合物層具有相同厚度。在另一具體實施例中,該聚合物層 與該第二聚合物層的厚度不同。 如前述,該可撓性骨複合材料包括包含鈣化合物的第 一含鈣層。該含鈣層可固定或物理性及/或化學性貼附於 該聚合物層的至少一面,諸如該第一面。下文茲說明將該 φ含鈣層固定或物理性及/或化學性貼附於該聚合物層的方 法。 該鈣化合物可爲孔狀或無孔。「孔狀」一辭包括但不 局限於大孔隙率(意指直徑大於或等於1 〇〇微米)、中孔 隙率(意指直徑小於1 〇〇微米但大於或等於1 〇微米)及 小孔隙率(意指直徑小於1 〇微米)。 該等孔隙可爲任何大小、形狀或分布,或在預定容許 値內。此外,該等孔隙可以互通或非互通。在一具體實施 例中,該等孔隙的直徑至高達75 0微米。在另一具體實施 -22- (19) 1374036 例中,該鈣化合物呈孔狀,其孔隙大小至高達約5 0 0微米 ,約75%該等孔隙的大小至少爲100微米,其餘25%的 孔隙大小不大於1 〇微米。 在該鈣化合物係固定或物理性及/或化學性貼附於該 聚合物層的情況下,大部分該鈣化合物的外表面未被該聚 合物覆蓋。該鈣化合物的有限外覆蓋率可以加強可再吸收 作用。 • 在一具體實施例中,相對於該含鈣層總重,該含鈣層 含有低於25重量%之聚合物。在另一具體實施例中,相 對於該含鈣層總重,該含鈣層含有低於1〇重量%之聚合 物。在另一具體實施例中,相對於該含鈣層總重,該含鈣 層含有低於1重量%之聚合物。較佳情況係,該含鈣層基 本上沒有聚合物。 在一具體實施例中’相對於該鈣化合物總重,該鈣化 合物具有低於約5重量%,較佳係低於約1重量%,更佳 φ係低於約0.5重量%的羥磷灰石。在另—具體實施例中, 該鈣化合物基本上沒有羥磷灰石。 在另一具體實施例中,該含鈣層可包括任何鈣骨水泥 。適用之鈣化合物的非限制性實例包括鈣之磷酸鹽、鈣之 硫酸鹽、鈣之碳酸鹽或其任何組合。較佳情況係,該含鈣 化合物係鈣鹽。 在一具體實施例中,該第一含鈣層包括一種磷酸鈣。 耗之憐酸鹽的非限制性實例包括非晶相磷酸鈣、結晶磷酸 鈴或其任何組合。 ⑧ (20) 1374036 • 在另一具體實施例中,該第一含鈣層包括磷酸鈣,其 中該磷酸鈣係包括CaHP〇4 · ηΗ2〇、α — Ca3 ( P04 ) 2、 α - bar - Ca3(P〇4) 2、^ - Ca3 ( P〇4 ) 2 '
Ca5 ( P〇4 ) 3OH ' Ca,〇 ( p〇4 ) 6 ( OH ) 2、Ca40 ( P04) 2 、CaP401 1、Ca2P2〇7、Ca ( H2P〇4 ) 2 · nH20 '
Ca8H2 ( P〇4 ) 6 · nH20或其任何組合,其中n係自0至5 之數。 φ 在另一具體實施例中,該第一含鈣層包括召-
Cas ( P〇4 ) 2。 在另一具體實施例中,該第一含鈣層包括沒—Ca3. (P〇4 ) 2,其中該;5 — Ca3 ( P04 ) 2基本上沒有羥磷灰石 〇 在另一具體實施例中,該第一含鈣層包括一種硫酸鈣 。該硫酸鈣可爲非晶相或結晶狀。適用之鈣的硫酸鹽非限 制性實例包括 c a ( S Ο 4 ) 、α — C a ( S 0 4 ) · 1 / 2 Η 2 Ο ' 馨/5 — C a ( S Ο4 ) · 1 /2 Η2 Ο或其任何組合。 適用於本發明的鈣化合物可爲任何形狀,包括例如球 形、立方體、楔形、長方形、圓柱形或其組合。在一具體 實施例中’該鈣化合物係球形。在另一具體實施例中.,該 鈣化合物係立方體。 該鈣化合物可爲任何大小或形狀的粒子或顆粒。該等 顆粒可購得或可藉由將鈣化合物碾磨或硏磨成所需之粒子 大小或粒徑而製得。該等顆粒可藉由例如過篩分類,獲得 所需之粒徑範圍(詳見尸 -24- (21) 1374036 «
Handbook > 第 21 章,第 1 3 -1 9 頁(Don. W. Green 編’ 1 984 ) ) 〇 在一具體實施例中,該等顆粒的平均直徑自約ο·05 mm至約1〇 mm。在另一具體實施例中,該等顆粒的平均 直徑自約0.075 mm至約5 mm。在另一具體實施例中’該 等顆粒的平均直徑自約0.075 mm至約〗mm。在另一具體 實施例中,該等顆粒的平均直徑自約1.4 mm至約2.8 mm φ 。在另一.具體實施例中,該等顆粒的平均直徑自約2.8 mm至約5.6 mm。在另一具體實施例中,該等顆粒的平均 直徑自約0 · 1 m m至約0 · 7 5 0 m m。 該鈣化合物的比表面積可變動。例如,當該鈣化合物 係一顆粒時,該比表面積自約0.1 m2 / g至約100 m2/ g ° ... 該第一含鈣層的數量與厚度可變動。通常,固定或物 理性及或化學性貼附於該聚合物層第—面的第—鈣化合 φ物數量足以提供所需之治療效果,同時仍保持該組成物的 必要性質’例如可撓牲與抗層離性。 在一具體實施例中,相對於該可撓性骨複合材料(即 ’該聚合物層對該第—含鈣層)總重,該鈣化合物的含量 自約1重量%至約99重量% ;在另一具體例中,相對於 可携性骨複合材料總重,該鈣化合物的含量自約5重量 %至約95重量% ;在另—具體實施例中,相對於該可燒 性骨複合材料總重’該鈣化合物的含量自約7 〇重量%至 約85重量%。 -25- (22) (22)1374036 在一具體實施例中’該第一含鈣層的厚度自約0·05 mm至約1〇 mm。在另一具體實施例中’該第一含鈣層的 厚度自約0.075 mm至約7.5 mm。在另一具體實施例中, 該第一含鈣層的厚度自約2.8 mm至約5.6 mm。在另一具 體實施例中,該第一含鈣層的厚度自約1.4 mm至約2.8 mm。在另一具體實施例中’該第一含鈣層的厚度自約0·1 mm 至約 0.750 mm。 鈣化合物粒子或顆粒位於或物理性及/或化學性貼附 於該聚合物層第一面的密度可變動。即,該鈣化合物粒子 間的間距可變動。例如,在一具體實施例中,大部分粒子 係在至少一其他鈣化合物粒子的約0.75 mm內。在另一具 體實施例中,大部分粒子係在至少一其他鈣化合物粒子的 約0.2 5 mm內。在另一具體實施例中,大部分粒子係在至 少一其他鈣化合物粒子的約0.1 mm內。在另一具體實施 例中,大部分粒子係與至少一其他鈣化合物粒子接觸。 可使用該第一含鈣層的任何適用厚度。例如,如下文 說明,將直徑大約等於所需第一含鈣層厚度的第一鈣化合 物顆粒固定或物理性及/或化學性貼附於該聚合物層一面 〇 此外,可使用一層以上之含鈣層形成該可撓性骨複合 材料。例如,該可撓性骨複合材料可包括固定或物理性及 /或化學性貼附於該聚合物層第二面的第二含鈣層。 該第二含鈣層包括第二鈣化合物。適用之第二鈣化合 物的非限制性實例包括上述作爲第一鈣化合物者。該第二 -26- ⑧ (23) (23)1374036 鈣化合物可與該第一鈣化合物相同或不同。 在一具體實施例中,該第二鈣化合物基本上沒有羥磷 灰石。在一具體實施例中,該第二鈣化合物係鈣鹽。 在另一具體實施例中,該第二鈣化合物係磷酸鈣。在 另一具體實施例中,該第二鈣化合物係沒—Ca3 ( P04 ) 2 。在另一具體實施例中,該第二含鈣層係 冷一Ca3(P〇4) 2’其中該/3— Ca3(P〇4) 2基本上沒有羥 磷灰石。 該第二含鈣層的厚度可與第一含鈣層的厚度相同或不 同。通常’該第二含鈣層的厚度自約0.05 mm至約1 〇 mm 〇 該可撓性複合材料在植入前或植入後可形成任何厚度 或形狀。 此外,在某些具體實施例中,可將二或多層彼此層叠 ’提供具有多層聚合物層與含鈣層的較厚複合材料。例如 ’在一具體實施例中’該多層可撓性骨複合材料可包括: (〇第〜複合材料,其包.括:具有第—面與第二面的第 一聚合物層;及固定或物理性及/或化學性貼附於該聚合 物層第—面的第—含鈣層;以及(b)第二複合材料,其 包括·具有第一面與第二面的聚合物層;及固定或物理性 及/或化學性貼附於該聚合物層第一面的第二含鈣層;其 中該弟一複合材料係固定或物理性及/或化學性貼附於該 第一複么料 一 口4料’形成該具有交錯聚合物層與含鈣層的多層 可撓性骨複合材料。亦可添加額外複合材料以形成該多層 (24) !374〇36 « 可撓性骨複合材料。用以製造該多層可撓性骨複合材料的 複合材料可相同或不同。 該多層可撓性骨複合材料可包括孔狀含鈣組份、無孔 含鈣組份或其組合。在一具體實施例中,該多層可撓性骨 包括孔狀含鈣組份與無孔含鈣組份。在另一具體實施例中 ’該多層可撓性骨包括孔狀含鈣組份。 該多層可撓性骨複合材料可包括可再吸收聚合物層、 % 非可再吸收聚合物層或其組合。較佳情況係,該多層可撓 性骨複合材料包括至少一層包含合成聚合物的可再吸收聚 合物層。 可使用任何適用方法將數種複合材料固定或化學性及 /或物理性貼附於彼此之上。例如,在一具體實施例中, 將二或多種可撓性複合材料彼此層疊時,所形成的複合材 料可視需要加熱之。例如,在某些實例中,該層疊複合材 料可在對流爐中以足以使該等聚合物層膠黏的時間與溫度 ϋ下加熱’然後冷卻之。在另一具體實施例中,對該經加熱 多層複合材料施加壓力。 • 在另一具體實施例中,可將該可撓性合成複合材料捲 起’例如捲成凝膠捲,以提供較厚複合材料。 在某些具體實施例中,於植入之前及/或期間,該可 撓性複合材料可展延與模塑’且可成型或裁切成所需形狀 。例如,在一具體實施例中,可使用例如刀、剪、截切機 或具有衝模的模衝片將該可撓性複合材料裁切成所需尺寸 及/或形狀。 (25) 1374036 攀 在一具體實施例中,該可撓性複合材料係於植入前载 '切成所需形狀。在另一具體實施例中,該可撓性複合材料 係於植入期間模塑成所需形狀。在另一具體實施例中,該 可撓性複合材料係於植入前裁切成所需形狀,並於植入期 間進一步模塑之。 或者’於製造之後,可處理本發明之可撓性骨複合材 料的一或多個表面’以改變該一或多個表面的—或多種化 φ 學及/或物理性質’例如增加表面親水性,或降低水之接 觸角。在一具體實施例中,該處理可包括曝露於可使該一 或多個表面變得具有反應性的能量源,例如諸如使用r射 線、電漿(例如例如諸如氧、二氧化碳、氬、氨.、氮等或 其組合之氣體)等輻射或其組合本身,或合倂曝露於其他 反應性環境(例如,存在空氣、氧、臭氧等等、曝露於化 學反應性官能基等等,或其組合)。 在一具體實施例中’本發明可撓性骨複合材料的—或 φ多個表面係使用氧電漿加以處理。在另一具體實施例中,
' 本發明可撓性骨複合材料的一或多個表面係使用二氧化碳 • 電漿加以處理。在另一具體實施例中,本發明可撓性骨複 合材料的一或多個表面係根據HYDRO LAST ™法處理而形 成接枝表面’該方法係購自MA之Billerica的AST
IndUStr】eS,InC.,其中將該—或多個表面曝露於一種氣體 電漿(諸如氧)中,然後與聚合/寡聚化合物反應,例如 聚(環氧院)/聚(烷二醇),諸如PE0/PEG或聚(烷 亞胺),諸如PEI。 -29- 1374036 * (26) ♦ 或者’或是此外,亦可視需要,於製造之後,經由 時間曝露於降解方法(諸如熱)之下,使本發明可撓性 複合材料熟成。在一具體實施例中,可進行此等選擇性 法’以例如改變本發明可撓性骨複合材料的體內或體外 降解動力學’或是達到所需之化學及/或物理性質。 圖I至·6顯示本發明可撓性骨複合材料之實施例, 中該鈣化合物係呈顆粒形式。圖1描述本發明範例可撓 φ 骨複合材料1其具有聚合物層30與含鈣層20,該含 層20包括呈顆粒22形式的鈣化合物。該聚合物層3〇 有第一面32與第二面34,該顆粒22係固定或物理性 /或化學性貼附於該聚合物層3 0的第一面3 2上。 圖2描述可撓性骨複合材料1〇之一具體實施例, 具有包栝顆粒22的第.一含鈣層20、聚合物層3〇與包 顆粒22的第二含鈣層25。如圖2所示,該第—含鈣層 與第二含鈣層25係分別固定或物理性及/或化學性貼 •於該聚合物層30的第一面32與第二面34上。 • 圖3描述本發明可撓性骨複合材料1〇之—具體實 • 例’其具有第一聚合物層30、包括顆粒22的含錦層 與第—聚合物層35。如圖3所示,該含銘層2〇係配置 該第一聚合物層30與第二聚合物層35之間。 圖4a與4b描述用於本發明可撓性複合材料的聚合 層之具體實施例’其中該聚合物層30係經衝孔。圖4a ’該聚合物層30中的衝孔40實質上呈圓形。圖々b中 聚合物層3 0中的衝孔4 2係呈隙縫形式。 長 骨 方 的 其 性 鈣. 具 及 其 括 20 附 施 20 於 物 中 -30- (27) 1374036 • » 圖5描述一多層可撓性骨複合材料5〇,其具有第— 複合材料10與層疊於該第一可撓性骨組成物1〇上的第二 複合材料15。圖5中顯示一多層可撓性骨複合材料。該 第—複合材料10具有第一聚合物層30與包括顆粒22且 固疋或物理性及/或化學性貼附於該聚合物層3〇 一面的 第二含鈣層20 ;而第二複合材料15具有第二聚合物層35 與包括顆粒22且固定或物理性及/或化學性貼附於該聚 φ 合物層35 —面的第二含鈣層25。 圖6描述本發明範例可撓性骨複合材料1〇,其具有 聚合物層30與包括顆粒22且固定或物理性及/或化學性 貼附於該聚合物層30 —面的含釣層20,其中該複合材料 係被捲起。 可視需要在本發明可撓性骨複合材料中或其上包括— 種治療物質’諸如但不局限於化學治療物質及/或生物治 療物質。在一具體實施例中,此等治療物質可存在該含鈣 (p層、該聚合物層或此二者之內或其上面。在另—具體實施 • 例中,該等治療物質可添加個別層、可預浸入此等層內、 . 可黏附於該等層表面,或是可以受控制防黏調配物( release formulation)形式包括在該等層之一或多層內。 該等治療物質的非限制性實例包括但不局限於抗微生物劑 、抗生素' 化學治療藥物、生長因子(特別是骨誘導生長 因子),諸如骨形態發生蛋白質、皮內細胞生長因子、胰 島素生長因子等等,或其組合。 當該治療物質係抗微生物劑時,該可撓性骨複合材料 -31 - (28) 1374036 中通常會存存一種,經常是不超過三種,常見的是不超過 兩種抗微生物劑。適用之抗微生物劑的非限制性實例包括 :抗阿米巴藥,例如胂噻醇(Arsthinol )、比亞拉米可(
Bialamicol)、卡巴胂(Carbarsone)、吐根酣驗( Cephaeline)、氯倍他胺(Chlorbetamide)、鱗酸氯奎寧 (Chloroquine)、氯酌諾撒胺(Chlorphenoxamide)、氯 四環素 '去氫吐根鹼、二溴丙脒(Dibromopropamidine ) 、二氯尼特(Diloxanide )、二苯他胂(Diphetarsone ) 、吐根鹼(Emetine)、煙曲黴素(Fumagillin)、格勞卡 汝賓(Glaucarubin)、甘鉍胂(Glycobiarsol) 、8 —經基 —7 —碑一5 —喹啉一擴酸(8-Hydroxy-7-iodo-5-quinoline-sulfonic acid)、氯碘 D奎啉(
Iodochlorhydroxyquin)、雙缺 D奎啉(lodoquinol)、巴龍 黴素(Paromomycin )、泛哇酮(P h an q u i η ο n e )、聚苯胂 酸(Polybenzarsol)、普洛帕脒(Pr〇Pamidine)、奎法 米德(Quinfamide )、思尼達唑(Scenidazole)、磺胺苯 胂(Sulfarside )、第克洛讓(Teclozan )、四環素、硫 代卡巴脒(Thiocarbamizine) '硫代卡巴胂( Thiocarbarsone) ' 梯尼達唑(Tinidaz〇le);抗生素,例 如胺基配糖體類抗生素(諸如艾米康絲菌素(Amikacin ) 、安痢黴素(Apramycin)、阿貝卡辛(Arbekacin)、巴 黴素(Bambermycins) 、丁 甘菌素(Butirosin)、戴貝卡 辛(Dibekacin)、二氫鏈黴素(Dihydrostreptomycin)、 福提米辛(Fortimicin)、簡他米辛(Gentamicin)、異 -32- (29) 1374036 帕米辛(Isepamicin)、卡尼亞黴素(Kaniamycin)、小 諾米辛(Micronomicin)、新徽素(Neomycin) 、~1--條
酸新黴素(Neomycin Undecylenate)、奈替米辛( Netilmicin )、巴龍黴素(Paromomycin)、核糖黴素( Ribostamycin)、希索黴素(Sisomicin)、觀黴素( Spectinomy cin )、鏈黴素(Streptomycin )、妥布黴素( Tobramycin)、丙大觀黴素(Trospectomycin))、安非 尼可類(Amphenicols)(疊氮氯黴素(Azidamfenicol) 、氯黴素 (Chloramphenicol )、氟甲擴氯黴素 ( Florfenicol)、甲磺氯黴素(Thiamphenicol))、袢黴素 (Ansamycins)(利法米德(Rifamide)、利法平( Rifampin )、利法黴素(Rifamycin)、利法潘平( Rifapentine)、利法西明(Rifaximin) ) 、—內醯胺 (碳頭孢嫌類(Carbacephems)、氯碳頭孢(Loracarbef ))、碳醯胺基類(carbapenems)(比阿培南( Biapenem)、亞胺培南(Imipenem)、美洛培南( Meropenem)、帕尼培南(panipenem))、頭孢菌素( Cephalosporins)(頭孢克洛(Cefaclor)、頭孢經氨节( Cefadroxil)、頭孢孟多(Cefamandole)、頭孢三嗉( Cefatrizine)、頭孢西酮(Cefazedone)、頭孢 D坐林( Cefazolin)、頭孢卡品醋(Cefcapene Pivoxil)、頭抱克 立定(Cefclidin )、頭孢地尼(Cefdinir )、頭孢妥侖( Cefditoren)、頭孢 D比汚(Cefepime)、頭孢他美( Cefetamet)、頭孢克肟(Cefixime)、頭孢尼諾新( -33- . (30) 1374036
Cefinenoxine)、頭抱地嗪(Cefodizime)、頭孢尼西( Cefonicid)、頭孢哌酮(Cefoperazone)、頭孢拉尼德( Ceforanide)、頭抱噻 β亏(Cefotaxime)、頭孢替安( Cefotiam)、頭抱哩蘭(Cefozopran)、頭孢咪哩( Cefpimizole)、頭孢匹胺(Cefpiramide)、頭孢匹羅( Cefpirome )、頭孢泊 fl弓醋(Cefpodoxime Proxetil)、頭 孢丙烁( Cefprozil)、頭孢沙定(Cefroxadine)、頭抱 磺啶(Cefsulodin )、頭孢他啶(Ceftazidime )、頭孢特 命(Cefteram)、孢替嗤(Ceftezole)、頭孢布坦( Ceftibuten)、頭孢哩 H ( Ceftizoxime)、頭孢三松( Ceftriaxone)、頭孢咲辛(Cefuroxime)、頭抱哩南( Cefuzonam )、頭孢乙腈鈉(Cephacetrile Sodium)、頭 孢氨千(Cephalexin)、頭孢來星(Cephaloglycin)、頭 孢噻卩定(Cephaloridine)、頭孢菌素(Cephalosporin)、 嚷抱黴素(Cephalothin )、頭孢匹林納(Cephapirin Sodium )、頭孢拉定(Cephradine)、皮西發星( Pivcefalexin))、頭孢黴素類(Cephamycins)(頭孢拉 宗(Cefbuperazone )、頭孢美哩(Cefmetazole )、孢米 諾(Cefminox)、頭孢替坦(Ceftetan)、頭孢西丁( Cefoxitin))、單環胺基類(monobactams)(胺曲南( Aztreonam )、卡蘆莫南(Carumonam )、替吉莫南( Tigemonam))、歐沙西芬類(Oxacephens)(氟氧頭孢 (Flomoxef)、羥羧氧酰胺菌素(Moxalactam))、青黴 素(Penicillins)(美西林(Amdinocillin)、美西林 〇比 -34- (31) 1374036 咲酸酯’(Amdinocillin Pivoxil)、阿莫西林(Amoxicillin )、氣亨西林(Ampicillin)、阿帕西林(Apalcillin)、 阿撲西林(Aspoxicillin)、疊氮西林(Azidocillin)、阿 洛西林(Azlocillin)、巴坎西林(Bacampicillin)、节 青黴酸(Benzylpenicillic Acid)、苄青黴素鈉(
B e n zy 1 p e n i c i II i n Sodium)、按干西林(Carbenicillin )、 卡節西林(Carindacillin)、氯甲西林(Clometocillin) 、氛哩西林(Cloxacillin)、環己西林(Cyclacillin)、 雙氯西林(Dicloxaci丨lin )、依匹西林(Epici 11 iη )、芬 貝西林(Fenbenicillin)、氟氯西林(Floxacillin)、海 他西林(Hetacill'in)、侖氛西林(Lenampicillin)、美 坦西林(Metampicillin )、甲氧苯西林鈉(M e t h i c i H in Sodium )、美洛西林(mezlocillin)、納西林鈉( Naacillin Sodium )、苯哩西林(Oxacillin)、培那西林 (Penamecillin)、氫姚化噴沙西林(Penethamate Hydriodide )、苯明青黴素 G ( Penicillin G Benethamine )、节星青黴素 G (Penicillin G Benzathine)、二苯甲胺 青黴素 G( Penicillin G Benzhydrylamine)、青黴素 G|5 (Penicillin G Calcium )、海巴青黴素 G ( Penici 11 in G Hydrabamine)、青黴素 G I丐(Penicillin G Potassium) 、普卡因青黴素(Penicillin G Procaine)、青黴素N ( Penicillin N) '青黴素 0 (Penicillin 0)、青黴素 V( PenicillinV)、苯基苯氧甲烯青黴素(PenicillinV b e n z a t h i n e )、海巴青黴素 V ( P e n i c i 11 i η V H y d r a b a m i n e -35- (32) 1374036 )、青_環素(Penimepicycline)、非奈西林鉀(
Ph e n e t h i c i 11 i n Potassium)、呢拉西林(P i p e r a c Π 1 i n )、
匹胺西林(Pivampici丨lin)、匹西林(Propicillin)、卩奎 那西林(Quinacillin )、磺苄西林(S u 1 b e n i c i 11 i η )、酞 胺西林(Tala mpicillin)、替莫西林(Temocillin)、替 凱西林(Ticarcillin))、利替培南(Ritipenem)、林可 醯胺類(Lincosamides)(克林達黴素(Clindamycin)、 林可黴素(Lincomycin))、巨環類抗生素(Macrolides )(阿奇黴素(Azithromycin)、卡波黴素(Capbomycin )、克拉黴素(Cl arithromycin )、第理黴素( Dirithromycin )、紅黴素(Eerythromycin)、醋硬脂紅 黴素(Erythromycin Acistrate )、依託紅徽素(
Erythromycin Estolate)、葡庚糖酸紅黴素(
Erythromycin Glucoheptonate)、乳糖酸紅黴素(
Erythromycin Lactobionate)、丙酸紅黴素( 籲 Erythromycin Propionate)、硬脂酸紅黴素(
Erythromycin Stearate)、交沙黴素(Josamycin)、樂益 克黴素(Leucomycin)、麥地黴素(Midecamycins)、美 歐卡黴素(Miokamycin)、歐黴素(Oleandomycin) '普 利黴素(Primycin)、羅他黴素(Rokitamycin)、玫瑰黴 素(Rosaramicin)、羅紅黴素(Roxithromycin)、史黴 素(Spiramycin)、妥蘭多黴素(Troleandomycin))、 多胜肽類(Polypeptides)(安福黴素(Amphomycin)、 枯草菌素(Bacitracin)、捲曲黴素(Capreomycin)、黏 (33) 1374036
桿菌素(Colistin)、恩黴素(Enduracidin)、恩維黴素 (Enviomycin)、夫沙芬淨(Fusafungine)、短桿菌狀 S (Gramicidin S )、短·桿菌肽(Gramicidin (s))、三徽 素(Mikamycin)、多黏菌素(Polymyxin)·、普利提那黴 素(Pristinamycin )、瑞斯托黴素(Ristocetin )、泰可 拉寧素(Teicoplanin)、硫鏈絲菌肽(Thiostrepton)、 結核放線菌素(Tuberactinomycin)、短桿菌酪狀( Tyrocidine)、酪毛黴素(Tyrothricin)、萬古黴素( Vancomycin)、紫黴素(Viomycin)、純黴素( Virginiamycin)、鋅枯草菌素(Zinc Bacitracin))、四 環素類(Tetracyclines)(阿呢環素(Apicycline)、氯 四環素(Ch 1 〇rt etracy c 1 i ne )、氯莫環素(Clomocycline )、去甲氯四環素(Demeclocycline)、多西環素( Doxycycline)、胍甲環素(Guamecycline)、賴氨環·素( Lymecycline)、甲氯環素(Meclocycline)、美他環素( Methacycline)、美諾環素(Minocycline) ' 經四環素( Oxytetracycline)、青呢環素(Penimepicycline)、匹呢 環素(Pipacycline)、氫 D比四環素(Rolitetracycline)、 山環素(Sancycline)、四環素(Tetracycline))、環絲 胺酸(Cycloserine)、莫匹羅星(Mupirocin)、結節因 (Tuberin ):合成抗菌劑,例如2,4一二胺基嘧啶類( 溴莫普林(brodimoprim)、德卓梭普林(Textroxoprim) 、曲美普林(Trimethoprim ))、硝基呋喃類(富來他頓 (Furaltadone)、卩夫 D坐氯銨(Furazolium Chloride)、硝 •37- (34) 1374036 9 咲拉定 (Nifuradene )、硝呋太爾(Nifuratei )、硝呋 復林(Nifurfoline)、呋喃那斯(N5furpirin〇丨)、硝呋拉 嗪(Nifurprazine )、硝呋托尼(Nifurtonio丨) '硝呋妥 因(Nitrofirantoin ) 、D奎諾酮類(Q u i n 〇丨0 n e s )與及同類 物(西諾沙星(Cinoxacin)、環丙沙星(ciprofloxacin) 、克林沙星(Clinafloxacin )、氟沙星(Difloxacin )、 依諾沙星(Enoxacin )、氟羅沙星(Fleroxacin )、氟甲 謂_ D奎(Flumequine)、格雷帕沙星(Grepafloxacin)、洛梅 沙星(Lomefloxacin )、米洛沙星(Mi丨oxac i η )、那氟沙 星(Nadifloxacin )、那第理希酸(N a d i 1 i x i c A c i d )、諾 弗拉沙星(Norflaxacin )、氧氟沙星片(〇fi〇xacin )、 歐索林酸(Oxolinic Acid) '帕珠沙星(Pazufloxacin) 、培氟沙星(Pefloxacin) 、D比呢酸(Pipemidic Acid)、 D 比略米酸(Piromidic Acid)、羅梭沙星(Rosoxacin)、 蘆氣沙星(Rufloxacin)、司帕沙星(Sparfloxacin)、替 馬沙星(Temafloxacin)、曲伐沙星(Trovafloxacin)) - 、磺醯胺類(乙醯磺甲氧基吡嗪、苄基磺醯胺、氯胺B、 氯胺T、二氯胺T、N2——甲基二甲磺胺異嘧啶、N4 —冷一 D -葡糖基磺胺、磺胺米隆(Mafenide ) 、4'—(甲基胺 磺醯基)磺胺、諾普磺胺(Norpylsulfainide)、苯二甲 醯乙醯磺胺、苯二甲醯磺胺噻唑、柳氮磺胺二甲嘧啶、琥 珀醯基磺胺噻唑、苯甲醯磺胺、乙醯磺胺、磺胺氯達嗪、 擴胺柯定(Sulfachrysoidine)、擴胺西汀(Sulfacytine) 、磺胺二嗪、磺胺戊烯(sulfadicramide )、磺胺二甲氧 -38-
(D (35) 1374036 ψ ·
暗 D定(Sulfadimethoxine )、碘胺多辛(Sulfadoxine)、 擴胺乙二哗(Sulfaethidole)、擴胺胍(Sulfaguanidine) 、磺胺二甲啞唑脒(sulfaguanol )、磺胺洛西酸( Sulfaloxic)、擴胺甲基唆Π定、擴胺甲氧唆D定(Sulfameter )、磺胺二甲嘧啶(Sulfamethazine)、磺胺甲基噻唑( Sulfamethizole )、擴胺甲氧邁陡(Sulfamethomidine)、 擴胺甲B惡n坐(Sulfamethoxazole)、擴胺甲氧喔D秦( Sulfamethoxypyridazine)、擴胺美曲(Sulfametrole)、 擴胺米柯定(Sulfamidochrysoidine)、擴胺嚼哩( Sulfamoxole )、磺胺、4 —柳氮磺胺二甲嘧啶、琥珀醯基 磺胺噻唑、苯甲醯磺胺、乙醯磺胺、磺胺氯達嗪、磺胺柯 定(Sulfachrysoidine)、磺胺西汀(Sulfacytine)、擴胺 二嗪、磺胺戊烯(sulfadicramide)、磺胺二甲氧嘧啶( Sulfadimethoxine )、.碘胺多辛(Sulfadoxine)、擴胺乙 二唑(Sulfaethidole )、磺胺胍(Su 1 faguani dine )、磺胺 二甲 |§gD坐滕(sulfaguanol)、擴胺洛西酸(Sulfaloxic) 、磺胺甲基嘧啶、磺胺甲氧嘧啶(Sulfameter)、磺胺二 甲嘧啶(Sulfamethazine )、磺胺甲基噻唑( Sulfamethizole )、擴胺甲氧邁 D定(Sulfamethomidine)、 擴胺甲H惡哩(Sulfamethoxazole)、擴胺甲氧喔嗪( Sulfamethoxypyridazine )、擴胺美曲(Sulfametrole)、 擴胺米柯定(Sulfamidochrysoidine)、擴胺喔哩( Sulfamoxole)、磺胺、4 -磺醯胺基水楊酸、N4 -磺胺醯 基磺胺(N4-sulfanilylsulfanilamide )、擴胺脲( -39- (36) 1374036
Sulfanilylurea) ' N—擴胺醯基—3,4 —二甲苯醯胺(N-Sulfanilyl-3,4-xylamide)、磺胺硝苯(Sulfanitran)、磺 胺匹林(Sulfaperine )、磺胺苯吡唑(Sulfaphenazole ) 、擴胺普羅林(Sulfaproxyline)、擴胺哦嗪( Sulfapyrazine)、磺胺吡啶、磺胺異噻唑(Sulfasomizole
)、擴胺均三D秦(Sulfasymazine)、擴胺噻哩、擴胺硫脲 、擴胺托拉米(Sulfatolamide)、擴胺二甲異喷B定( Sulfisomidine)、磺胺異噁唑(Sulfisoxazole))、硕類 (醋胺苯碼(Acedapsone)、醋地硕(Acediasulfone)、 磺胺苯砸鈉(Acetosulfone Sodium)、胺苯硕(.Dapsone )、地百裡硕(Diathymosulfone)、葡胺苯硕鈉( Glucosulfone Sodium)、苯丙硕(Solasulfone)、號拍胺 苯硕(Succisulfone )、磺胺酸、對磺胺醯基苄胺(p-Sulfanilylbenzylamine )、亞擴胺苯碾鈉(Sulfoxone Sodium )、噻碼(Thiazolsulfone))、氯福克酣( Clofoctol )、海克西定(Hexedine )、烏洛托品( Methenamine)、無水亞甲基檸檬酸烏洛托品( Methenamine Anhydromethylenecitrate)、馬尿酸烏洛托 品(Methenamine Hippurate)、苦杏仁酸烏洛托品( Methenamine Mandelate)、擴基水楊酸烏洛托品( Methenamine Sulfosalicylate ) ' 硝羥 D奎啉(Nitroxoline )、牛擴羅定(Taurolidine)、西波莫(Xibomol):抑 制痲瘋抗菌劑,諸如醋胺苯碾(Acedapsone)、磺胺苯硕 鈉(Acetosulfone Sodium)、氯法齊明(Clofazimine)、 -40- (37) 1374036 胺苯硕(Dapsone)、地百裡硕(Diathymosulfone)、葡 胺苯硕鈉(Glucosulfone Sodium)、大風子酸、苯丙硕( Solasulfone)、號拍胺苯砸(Succisulfone)、亞擴胺苯 碼鈉(Sulfoxone Sodium )、抗真菌劑,諸如烯丙胺類、 布替萘芬(Butenafine)、萘替芬(Naftifine)、特比萘 芬(Terbinafine )、咪唑類(例如,聯苯苄唑(
Bifonazo丨e )、布康哗(Butoconazole )、氯檔妥因( Cholordantoin)、氯米達 D坐(Chlormidazole)、氯康哩 (Cloconazole)、克霉吨(Clotrimazole)、益康哩( Econazole)、恩康哩(Enilconazole)、芬康 Π坐( F enticonazole ) '氟曲馬哩(Flutrimazole)、異康卩坐( Isoconazole)、酮康哩(Ketoconazole)、拉諾康哩( Lanoconazole )、咪康哩(M i c ο n a ζ ο 1 e )、奧康哩( Omoconazole) '硝酸奧昔康哩(Oxiconazole Nitrate) ' 舍他康哩(Sertaconazole)、硫康哩(Sulconazole)、噻 φ康唑(Tioconazole )、硫胺甲酸類(托昔拉酯(Tolcilate )、托林達醋(Tolindate )、托萘醋(Tolnaftate ))、 三哩類(氟康嗤(Fluconazole)、伊曲康哩( Itraconazole)、沙康卩坐(Saperconazole)、特康哩( Terconazole) ) 、nyn定瑣辛 Acrisorcin、阿莫羅芬(
Amorolfine)、珍尼柳醋(Biphenamine)、溴柳氯苯胺 (Bromosalicylchloranilide) 、丁 氯柳胺(Buclosamide) 、丙酸銘、氣苯甘醒(Chlorphenesin)、環哏酮胺( Ciclopirox)、可洛奎(Cloxyquin)、共聚石臘酸醋( ⑧ -41 - (38) 1374036
Coparaffinate)、二鹽酸地馬哩(Diamthazole Dihydrochloride)、依沙醯胺(Exalamide)、氟胞嘴 D定 (Flucytosine)、哈雷他吨(Halethazole)、海克替 B定( Hexetidine)、氯氟卡班(Loflucarban)、硝咲太爾( Nifuratel )、碑化鉀、丙酸、吼n定硫酮(Pyrithione)、 水楊酸苯胺、丙酸鈉、舒苯汀(Sulbentine)、替諾尼口坐 (Tenonitrozole )、甘油三乙酸酯、烏糾索因(Uj othoiη )、十一烯酸、鈉酸鋅等等。 適用於本發明之其他抗微生物劑包括:Q-內醯胺酶 抑制劑(例如克拉椎酸(C 1 a v u 1 a n i c A c i d )、舒巴坦(
Sulbactam)、他π坐巴坦(Tazobactam));克羅蘭利膽 醇(Chldramphenicols)(例如、阿齊當利膽醇( Azidamphenicol )、氯黴素(Chloramphenicol)、塞利膽 醇(Thiaphenicol )):褐霉菌酸;合成藥劑,諸如曲美 普林(Trimethoprim ),視需要與磺醯胺類倂用)與硝基 咪唑類(例如甲硝唑(Metronidazole )、梯尼達唑( Tinidazo】e)、硝基嗎咪哗(Nimorazole):抗分枝桿菌 藥(例如,捲曲黴素(Capreomycin) '氯法齊明( Clofazimine)、胺苯硒(Dapsone)、乙胺丁醇、異煙肼 (Isoniazid) 、DttD秦醯胺(Pyrazinamide)、利福布汀( Rifabutin)、利福平(Rifampicin)、鏈黴素( Streptomycin)、硫代醯胺類);抗病毒劑(例如,亞克 洛韋(Acryclovir ) '金剛烷銨、齊多夫定(
Azidothymidine )、更昔洛韋(Ganciclovir)、碘音( -42- ⑧ (39) 1374036 參 «
Idoxuridine)、利巴韋林(Tribavirin) ' 三氟尿苷( Trifluridine)、阿糖腺甘酸(Vidarabine));干擾素( 例如,干擾素α、干擾素/9 ):及防腐劑(例如,氯己定 (Chlorhexidine)、龍膽紫、奧替尼陡(Octenidine)、 波維東碘(Pivodone Iodine)、四級銨化合物、磺胺嘧啶 銀、二氯苯氧氯酣(Triclosan))。 該等治療物質可進一步包括生物治療物質,諸如例如 φ ,蛋白質。在一具體實施例中,可添加骨相關蛋白質以改 善該組成物的物理性質,強化再吸收、血管形成、進入細 胞與增殖、礦化、骨形成、破骨細胞及/或成骨細胞生長 等等。特別重要的蛋白質係不同種類的膠原蛋白,尤其是 第1型。其他蛋白質包括骨連接蛋白、骨唾液蛋白(Bsp )、〇:— 2HS -糖蛋白 '骨鈣素(Bgp)、基質GU蛋白 、骨磷糖蛋白、骨磷蛋白、骨蛋白聚糖、原脂質類、骨形 態生成蛋白質(例如BMP-1、- 2A、-2B、一3、- 3b 、— 4、— 5、— 6、— 7、— 8、— 8b' — 9、— 10、— 11、 一 12、— 13、一 14、-15)、軟骨誘導因子、血小板衍生 生長因子(PDGF— 1、一 2)、內皮細胞生長因子(ECGF —1、一 2a、— 2b)、骨骼生長因子(SKF=IGF-2)、 似胰島素生長因子(IGF - 1、IGF — 2 )、纖維母細胞生 長因子(ODGF— 1、— 2、一 3、— 4' 一 5、一6、— 7、 -8、一9、一10、一11、一12、一13、一 14、一 15、一 16 、一17、一 18、— 19、— 20、一 21、— 22、— 23)、集落 刺激因子、轉化生長因子(例如TGF — /3 )、血管內皮生
-43- (40) 1374036 長因子(VEGF)、生長/分化因子(GDF —】、— ' —6、一 7、一 8、一 9、一 9B、一 10、一 11、一 1: )、成骨蛋白(〇1>-1=81^?—7、0?—2=8河?--3 = BMP- 8b )、骨生長激素、甲狀旁腺激素( 、胰島素、降鈣素等等。該等蛋白質亦可包括與軟 之蛋白質,諸如軟骨鈣化蛋白質;與牙本質相關之 ,諸如磷蛋白、糖蛋白及GU蛋白質;或與珐瑯質 蛋白質,諸如齒釉蛋白與齒釉質蛋白。用於本發明 結構蛋白質包括但不局限於纖維蛋白、血纖蛋白原 白、微管蛋白、彈性蛋白等等。在一具體實施例中 別或一起使用在血漿或血清中之血液蛋白,例如血 在某些具體實施例中,該治療物質可進一步包 蛋白質生長因子,諸如前列腺素與史他汀(statins 如 Simvastatin、Lo vastatin ) 。 在一具體實施例中,該治療物質係一種生長因 如但不局限於骨形態生成蛋白質、內皮細胞生長因 胰島素生長因子等等,或其組合。 可使用任何適用量之治療物質。例如,存在該 骨複合材料中的抗微生物劑的用量可足以至少使一 其範圍內的微生物生長速率比對照組降低的量。在 體實施例中,該抗生素用量係足以提供直徑至少約 ’通常至少約1 5 mm之抑制區的量,該範圍係如p 人提出之美國專利5,968,2 5 3號所述的抗菌活性化 3 ' - 5 >'-16 8 ' 〇p PTH ) 骨相關 蛋白質 相關之 的重要 、角蛋 ,可個 清蛋白 括一非 )(例 子,諸 子、似 可撓性 產物在 許多具 10 mm 〇 s e r 等 驗所測 , (41) 1374036 得’該案全文係以提及的方式倂入本文中。該可撓性骨複 合材料中所使用之治療物質用量可視諸如修復位置、病患 年齡與健康狀況等等因素而定,且可由熟悉本技術之人士 決定。 包括治療物質的可撓性骨複合材料亦可用於將此治療 物質局部輸送至例如重要生理位置。例如,包括抗微生物 劑的可撓性骨複合材料可用於需要長時間將一種抗微生物 φ 劑釋放至局部環境的方法,其中該段時間通常至少約5天 ’經常至少約10天,更常見的是至少約2〇天,且該可撓 性骨複合材料可將該抗微生物劑釋放至其局部環境長達 4 〇天以上’端視製備該產物的特定組成物而定。因此, 已發現該包括抗微生物劑的可撓性骨複合材料可作爲長時 間輸送抗微生物劑的載體,即,作爲抗微生物劑儲存處, 其中需要長時間局部輸送抗微生物劑。已發現該主題組成 物特別適於作爲骨組織,尤其是疏鬆骨組織的局部抗微生 φ物劑輸送載體。 -本發明亦包括用於製造包括聚合物層與含鈣層的可撓 ,性骨複合材料之方法。 可藉由形成上述之聚合物層,並在該聚合物層第一面 上沉積第一鈣化合物,在該聚合物層上形成第一含鈣層, 製造該可撓性骨複合材料。可使用任何適用方法將該鈣化 合物固定或物理性及/或化學性貼附於該聚合物層第一面 的表面上。例如,在一具體實施例中,可以在足以使位於 該第一聚合物層表面上的鈣化合物物理性及/或化學性貼 -45- (S) (42) 1374036 附或黏附於表面的時間與溫度,加熱該聚合物層該鈣化合 物,例如加熱該聚合物層直到其變膠黏,將該鈣化合物固 定或物理性及/或化學性貼附於該聚合物層的第一面。在 另一非限制性實例中,該鈣化合物係固定或物理性及/或 化學性貼附於一凝膠(其形成該第一聚合物層)表面,形 成該第一聚合物層上的含銘層。視需要,將該耗化合物固 定或物理性及/或化學性貼附於該聚合物層的方法可包括 | 施加壓力" 在一具體實施例中,該可撓性骨複合材料係由下列方 法製得:形成具有第一面與第二面的聚合物層;使第—耗 化合物與該聚合物層的第一面接觸,形成第一中間產物複 合材料;並在足以使該第一鈣化合物固定或物理性及/或 化學性貼附於該聚合物層之第一面的溫度下加熱該中間產 物複合材料。 在一具體實施例中’本發明之聚合物層可於與該耗化 0合物接觸前先行衝孔。 在另一具體實施例中,本發明包括用於製造包括具有 第一面與第二面之經衝孔聚合物層的可撓性骨複合材料的 方法’其包括對一聚合物層衝孔,以形成經衝孔聚合物層 ’加熱該經衝孔聚合物層;使該第一鈣化合物與該經衝孔 聚合物層的第一面接觸’形成第—中間產物複合材料;並 使該第一中間產物複合材料冷卻至足以使該第—鈣化合物 固定或物理性及/或化學性貼附於該經衝孔聚合物層之第 一面的溫度,提供第一含鈣層。 -46- (43) 1374036 在一具體實施例中,以足以使該聚合物層變膠黏的時 間與溫度加熱該經衝孔聚合物層·» 用於製造可撓性骨複合材料的另一方法包括:將一種 包括聚合物與溶劑的溶液澆鑄於一防黏表面;使該溶液形 成凝膠;使銘化合物與該凝膠的第一面接觸;並使該溶劑 自該凝膠蒸發’形成含耗層固定或物理性及/或化學性貼 附於該聚合物層第一面的可撓性骨複合材料。 | 該可撓性骨複合材料經製備之後,可於減壓下乾燥, 在適當濕氣與經消毒下包裝。 本發明另一實施樣態包括用於貯存、製備、混合及/ 或支配本發明複合材料的套組或包裝系統。 本發明之可撓性骨複合材料可作爲或用於可植入醫療 裝置等等。特別是,此等應用或裝置可包括但不局限於骨 '豁移植(例如骨骼移植或骨骼移植人工骨骼)或骨骼空 腔塡充劑,其可單獨使用或與一或多種其他習用裝置倂用 φ ,此等習用裝置可包括但不局限於骨固定板(例如,顱顏 、顎面、整形、骨骼等);螺絲;大頭針;固定夾、固定 釘、骨釘、栓或桿、錨(例如,用於縫合、接骨等等); 支架、氣味、網狀結構(例如剛性、可伸展、機織、針織 、織造等);海綿體、用於細胞膜包覆或組織工程的植入 體、藥物輸送(例如,載劑、骨骼長入誘導催化劑,諸如 形態生成蛋白質、生長因子、胜肽等、抗病毒劑、抗性素 等):單絲或多絲結構、薄板、塗層、膜片(例如孔狀、 微孔狀、可再吸收等等);發泡體(例如開放式孔或密閉 (44) 1374036 式孔)'螺絲強化、顱骨重建:及/或其組合。用於或倂 用可植入醫療裝置時,該可撓性骨複合材料較佳係可生物 吸收及/或可再吸收。 任何植入該可撓性骨複合材料的方法均可使用。例如 ’在一具體實施例中,可將該可撓性骨複合材料配於一空 腔上、將其置於骨上、捲起並塡入一空腔中、摺起並塡入 —空腔中等等。 _ 在一具體實施例中,本發明包括用於治療有需求之病 患的硬組織缺損,例如骨骼或軟骨,包括將一治療量的本 發明可撓性骨複合材料植入該缺損內。此等骨骼缺損包括 但不局限於骨空腔、骨骼移植、脊椎缺損、整形缺損或顎 面缺損。在一具體實施例中,該骨骼缺損係骨空腔》 在另一具體實施例中,本發明包括用於治療骨骼缺損 的方法’其另外包括使用具有該可撓性複合材料的固定裝 置。固定裝置的非限制性實例包括板、螺絲、大頭針、栓 φ 、桿、支撐器或其任何組合。 在另一具體實施例中,本發明包括用於吸取有需求之 病患的骨髓的方法’其包括將治療量之可撓性骨複合材料 植入該骨髓附近區域。例如,在—具體實施例中,可如上 述將該可撓性骨複合材料浸於吸取骨髓並植入之。 實施例 兹參考下列實施例說明本發明較佳具體實施例與對照 貫例’其僅用於範例說明,不限制本發明範圍。 -48- ⑧ 1374036 β 臂 * (45) 實施例1
使用 Carver Compression Press 型號 3895 號(印第安 那州Wabash之Carver,Inc.)將約2·94 g之特性黏度約 1.5 dl/g的70: 30聚(L 一乳交酯一共聚—ε —己內酯 )(PURASORB ®,Purac,Lincolnshire, IL 所製)成形 成膜,其中係將該聚合物置於噴有Price-Dricscoll抗膠黏 脫模劑(康乃狄克州 Waterford 之 Price - Driscoll Corp.) 的不鏽鋼塡隙片(約0.12 mm )間,並使用約0.1 1 mm的 黃銅塡隙片控制該聚合物厚度,並使用下列壓製條件:壓 板預設點溫度約150 °C ;載重約10,000 kg;抽吸約80% ;閉模時間約5 0秒。壓製之後,使該膜在一冷卻板上冷 卻,提供厚度約0.1 〇至約0.12 mm的聚合物層》 實施例2 如實施例1所述,自約2.99 g之70: 30聚(L —乳 交酯一共聚_ ε -己內酯)製備聚合物層,但其中將 Kapton ®聚醯亞胺脫模薄板(德拉瓦州Wilmington之 DuPont)(約1密耳厚)置於該聚合物與該不鏽鋼之間。 以冷空氣冷卻之後,所形成聚合物層很容易地自該等薄板 脫除,提供厚度約0.15至約0.18 mm且直徑爲130 mm的 聚合物層。 實施例3 ⑧ (46) 1374036 4
V 如實施例2所述,自約2 · 9 6 g之7 0 : 3 0聚(L 一乳 父醋一共聚一 ε —己內酯)製備聚合物層,但其中該載重 約15, 〇〇〇 kg’且閉模時間約60秒。所形成聚合物層厚度 約〇·13至約015 mrn,且直徑約143 mm» 實施例4 如實施例3所述’自約2.9 5 g之7 0 : 3 0聚(L —乳 φ父酯-共聚一 £ 一己內酯)製備聚合物層’但其中該載重 約20,〇〇〇 kg。所形成聚合物層顯示出具有氣泡,其係因 固定期間聚合物的塗膠量過薄所致。該聚合物層的厚度約 0-13 至約 〇.i4mm,直徑約 146 mm。 實施例5 如實施例3所述’自約2 · 9 7 g之7 0 : 3 0聚(L 一乳 交醋一共聚一 ε -己內酯)製備聚合物層,但其中該壓板 φ預設點約158 °C ’且載重約20,000 kg。所形成聚合物層 的厚度約0.1〗至約0.14 mm,直徑約149 mm。 實施例6 如實施例1所述,自約2.9 5 g之7 0 : 3 0聚(L —乳 交酯一共聚- ε -己內酯)製備聚合物層,但其中該壓板 預設點約1 6 0 °C,載重約2 4,〇 〇 〇 k g,且閉模時間約7 0秒 。所形成聚合物層的厚度約〇. n至約〇 . 1 3 m m,直徑約 15 0mm。 -50- (47) 1374036 實施例7 如實施例6所述自約3.40 g之70 : 3 0聚(L—乳交 酯-共聚一 £ -己內酯)製備聚合物層。所形成聚合物層 的厚度約0.11至約直徑約160 mm。 實施例8 φ 如實施例7所述自約3.43 g之70 : 3 0聚(L一乳交 酯-共聚- ε -己內酯)製備聚合物層,但該閉模時間約 7 5秒。所形成聚合物層的厚度約〇 · 1 1至約〇 . 1 3 m m ’直 徑約1 6 0 m m。 實施例9 如實施例8所述自約3.40 g之70 : 3 0聚(L —乳交 酯一共聚一 ε -己內酯)製備聚合物層,提供厚度約0.11 〇至約0.13 mm,直徑約160mm的聚合物層。 實施例]〇 如實施例7所述自約3 · 5 1 g之7 0 : 3 0聚(L —乳交 酯一共聚一 ε —己內酯)製備聚合物層,提供厚度約〇.Π 至約0.1 3 m m,直徑約1 6 0 m m的聚合物層。 實施例1 1 如實施例7所述自約3.49 g之70 : 3 0聚(L一乳交 -51 -
CD (48) (48)1374036 酯一共聚一 ε -己內酯)製備聚合物層,提供厚度約〇. 11 至約0.13 mm,直徑約160 mm的聚合物層。 實施例]2 如實施例7所述,製備70: 30聚(L —乳交酯一共聚 _ ε _己內酯)共聚物的聚合條(厚度約0.1 m.m;寬度 約10 mm),並置於保持約37 °C之磷酸鹽緩衝溶液(約 pH値7.4 )中。自該緩衝液取出該等條狀物,並測量其抗 張強度。詳見表1。 表1、保存在磷酸鹽緩衝溶液(pH値〜7.4)中之70: 30聚 (L-乳交酯-共聚-ε-己內酯)共聚物的抗張強度變化 週數 抗張強度尖峰 屈服強度 模數 (MPa ) 0.2 %偏移(MPa) (MPa) 0 42.4 1 0.8 3 60.9 2 3 0.0 7.6 14 1.0 4 27.8 7.1 133.9 8 15.7 6.5 147.9 12 5.2 3.8 117.9 實施例1 3 如實施例2所述,製備6 0 : 1 4 : 26之聚(乙交酯— 共聚一二氧雜環己酮一共聚-碳酸丙二酯)的聚合物層, 但其中該壓板預設點約160°C,載重約24,000 kg,且該 -52- (49) (49)1374036 閉模時間約70秒。 實施例1 4 將實施例13之60: 14: 26之聚(乙交醋一共聚一二 氧雜環己酮-共聚-碳酸丙二酯)共聚的聚合條(直徑約 0.1 mm,寬度約10 mm)置於保持約37 °C之磷酸鹽緩衝 溶液(約pH値7.4)中。自該緩衝液取出該等條狀物, 並測量其抗張強度。結果示於表2。 表2、保存在磷酸鹽緩衝溶液(pH値〜7.4 )中之60 ·· 14 :26之聚(乙交酯-共聚-二氧雜環己酮-共聚-碳酸丙二酯 )共聚物的抗張強度變化 週數 抗張強度尖峰 屈服強度 模數 (MPa) 0.2% 偏移(MPa) (MPa) 0 62.1 16.4 3 5 5.7 1 49.5 16.9 3 52.6 2 23.9 15.1 4 12.0 實施例1 5 實施例Π之聚合物層衝孔作用係將其置於一軟基材 上,使用1/16”之衝壓機與大錘,在該聚合物層中衝壓 出距離約4—5 mm的約1/16" ( 1.5875 mm)的孔。所形 成之經衝孔聚合物層置於/3 — Ca3 ( P04 ) 2層(購自賓州 Paoli之Synthes,商標爲chronOS™ )之間,且其直徑約 -53- (50) 1374036 1 · _4至約2.8 m m。將該層疊組成物置於不鏽鋼模中,以中 間紙黏合劑將該模固定在一起。將該模置入約13〇t之對 流爐中約1 5分鐘,提供具有經衝孔之可再吸收聚合物層 的可撓性骨複合材料。 實施例1 6 如實施例15所述製備可撓性骨複合材料,惟該聚合 φ 物層未經衝孔,且該模係於約]4(TC之對流爐中加熱。 實施例1 7 如實施例]6所述製備可撓性骨複合材料,惟該聚合 物層係以間距約4 - 5 mm的柳葉刀加以縱割(長度約2 至約3 mm )。 實施例1 8 如實施例15所述製備可撓性骨複合材料,惟該 chronOS ™顆粒的直徑約〇_5至約0.7 mm,且該模係於約 1 45 °C之對流爐中加熱約20分鐘。 貫施例19 — 22--表面處理對於複合材料攝入血液的影響 以實施例18之大致相同方式製造四種本發明可撓性 骨複合材料(但得自實施例II之聚合物層的直徑約25〇 mm,該聚合物層厚度自約〇.〇9至約〇·η mm,且該聚合 物重量顯示出的改變與直徑增加相稱),並註爲實施例 -54 - (51) 1374036 19一 22。實施例19的複合材料含有原有或未經處理的表 面,而實施例20 — 22之複合材料的表面係經處理,分別 經由曝露於氧電漿、二氧化碳電發及HYDROLAST™處理 (其係一種電漿/接枝處理法,由麻州Billerica之AST Products,Ins.所售,其特別說明於美國專利5,700,559、 5,807,636與5,837,377號’該等專利案全文係以提及的方 式併入本文中)’如此使其更具親水性。該氧與二氧化碳 Φ 電漿處理的條件與該hydrolast ™處理法的電漿部分中 所使用條件相似,此等實例中包括壓力約30毫托耳且功 率約250瓦之RF電漿。 就實施例19 一 22各者而言,某些可撓性骨複合材料 係以剛製造完的狀態使用,而其他可撓性骨複合材料係在 約45 °C熟成約2 1天後使用》在環境條件下,將實施例]9 一 22可撓性骨複合材料(剛製造以及經熟成均有)浸於 牛血中約3 0秒,以測量攝入血液水準。下表3顯示其結 (ϋ果。平均攝入値代表約15個獨立樣本的平均。 -55- (52) 1374036 表3、本發明可撓性骨複合材料的牛血攝入水準--經處 VS.未經處理,以及經熟成 vs.剛製造者 實施例 處理 熟成 平均攝入水準 1 9 Μ Y 54% N 51% 20 〇2電漿 Y 68% N 64% 2 1 C〇2電漿 Y 59% N 61 % 22 HYDROLAST ™ Y 64% N 69%
雖然參考特定較佳具體實施例說明本發明,但顯而易 見的是在不違背本發明範圍,特別是附錄申請專利範圍所 界定之範圍情況下’熟悉本技術之人士可進行修改與變化 【圖式簡單說明】 圖1描述具有一聚合物層與一含耗層之本發明可撓性 骨複合材料具體實施例的斷面圖。 圖2描述具有第一含耗層 '一聚合物層與第二含銘層 之本發明可撓性骨複合材料具體實施例的斷面圖。 圖3描述具有第一聚合物層、—含鈣層與第二聚合物 層之本發明可撓性骨複合材料具體實施例的斷面圖。 rs) 、〜! -56- (53) 1374036 圖4a描述本發明聚合物層之具體實施例的透視圖’ 其中該層係經衝有許多孔。 圖4b描述本發明聚合物層之具體實施例的透視圖, 其中該層係經衝有許多隙縫。 圖5描述具有第—可撓性骨複合材料與第二可燒性骨 複合材料之本發明多層可撓性骨複合材料的斷面圖。 圖6描述具有一聚合物層與—含銘層之本發明範例可 _携性骨複合材料的斷面圖,其中該複合材料係被捲起。 【主要元件符號說明】 10:可撓性骨複合材料 15 :第二複合材料 2〇 :含鈣層 22 :顆粒 25 :第二含鈣層 ^ 3 〇 :聚合物層 32 :第一面 34 :第二面 35 :第二聚合物層 衝孔 4 2 :衝孔 50:多層可撓性骨複合材料 -57-
Claims (1)
- IW4036 1年ク月ί石日修正本 附件3Α :第094 1 1 9 1 1 3號申請專利範圍修正本 民國101年7月 16 日修正 十、申請專利範圍 1.—種可撓性骨複合材料,其包括: (a) 第一聚合物層’其包括合成可再吸收聚合物, 且具有第一面與第二面;以及 (b) 第一含鈣層,其包括以化學性、物理性或以此 φ 二種方式貼附於該聚合物層的第一面的召―Ca3(P04)2顆 粒’其中該第一聚合物層中具有衝孔,其中該第一含鈣層 實質上沒有聚合物’及其中該顆粒之外表面之大部分沒有 被聚合物覆蓋。 2· —種可撓性骨複合材料,其包括: (a)第一聚合物層,其包括合成可再吸收聚合物, 且具有第一面與第二面;以及 (b )第一含鈣層,其包括以物理性、化學性或以此 Φ 二種方式貼附於該聚合物層的第一面的鈣化合物顆粒,其 中該第一聚合物層中具有衝孔,及其中該鈣化合物之外表 面之大部分沒有被聚合物覆蓋。 • 3.如申請專利範圍第2項之可撓性骨複合材料,其 中該第一含鈣層包括實質上沒有羥磷灰石的鈣化合物。 4.如申請專利範圍第3項之可撓性骨複合材料,其 中該含耗化合物包括憐酸耗、硫酸釣、碳酸釣或其任何,組 合。 5-如申請專利範圍第4項之可撓性骨複合材料,其 1374036 中該磷酸鈣係非晶相磷酸鈣、結晶磷酸鈣或其組合。 6. 如申請專利範圍第4項之可撓性骨複合材料,其 中該磷酸鈣係包括:CaHP04· πΗ2〇、a - Ca3(P〇4)2' α —bar — Ca3(P〇4)2 ' 沒 一 C a3 (P 〇4) 2、C a,(P O 4) 3 〇 pj、 Cal0(PO4)6(〇H)2、Ca4〇(P〇4)2 ' CaP4〇n ' Ca2P2〇7 , Ca(H2P〇4)2 · nH20、Ca8H2(P〇4)6 · nH20 或其任何組合, 其中n係自0至5之數。 7. 如申請專利範圍第6項之可撓性骨複合材料,其 另外包括化學治療物質、生物治療物質或其組合。 8. 如申請專利範圍第2項之可撓性骨複合材料,其 中該衝孔包括具有約0.4 mm至約6.5 mm直徑之孔。 9. 如申請專利範圍第8項之可撓性骨複合材料,_ 中該孔具有約0.8 mm至約3.5 mm之直徑。 10. 如申請專利範圍第8項之可撓性骨複合材料,其 中該孔具有約1.0 mm至約2 mm之直徑。 V 1 I ·如申請專利範圍第1 〇項之可撓性骨複合材料, 其中該孔具有約1.5 mm之直徑。 1 2 _如申請專利範圍第2項之可撓性骨複合材料, 中該衝孔包括具有約0.5 mm至約1〇 mm長度之切q。 I3·如申請專利範圍第12項之可撓性骨複合材半斗 其中該切口具有約1 mm至約5 mm之長度。 I4·如申請專利範圍第13項之可撓性骨複合材米斗 其中該切口具有約2mm至約3 mm之長度。 15.如申請專利範圍第2項之可撓性骨複合材料, -2- B74036 Φ該聚合物層實質上沒有鈣化合物。 16·如申請專利範圍第2項之可撓性骨複合树料, 中該第~含鈣層實質上沒有聚合物。 17.如申請專利範圍第2項之可撓性骨複合材料, 中該顆粒具有約0.05 mm至約10 mm之平均直徑。 1 8 .如申請專利範圍第2項之可撓性骨複合材料, 中該顆粒具有約1_4 mm至約2.8 mm之平均直徑。 1 9.如申請專利範圍第2項之可撓性骨複合材料, 中該顆粒具有約2.8 mm至約5.6 mm之平均直徑。 2〇·如申請專利範圍第2項之可撓性骨複合材料, 中該耗化合物具有約〇. ;! m2/g至約1〇〇 m2/g之表面積。 2 1 ·如申請專利範圍第2項之可撓性骨複合材料, 中該第一聚合物層具有約11(rc至約165γ之融熔溫度 22,一種具有外部及內部之多層可撓性骨複合材料 其包括: (a)第一複合材料,其包括: 弟聚合物層,其包括合成聚合物,且具有第—面 第二面;以及 弟曰耗層,其係物理性、化學性或以此二種方式貼 附於該聚合物層的第〜面; (”第二複合材料,其包括: 第—水口物層’其包括合成聚合物,且具有第-面與 弟一面,以及 第a鈣®其係物理性、化學性或以此二種方式貼 其 其 其 其 其 其 與 -3- 1374036 附於該第二聚合物層的第一面, 其中,該第一複合材料係物理性、化學性或以此二種 方式貼附於該第二複合材料,形成具有聚合物層與含鈣層 交錯的多層可撓性骨複合材料,其中該第一聚合物層及該 第二聚合物層中之至少一者具有衝孔,其中該第一含鈣層 及該第二含鈣層中之至少一者實質上沒有聚合物,其中該 第一含鈣層及該第二含鈣層中之至少一者包含鈣化合物顆 粒,及其中該鈣化合物之外表面的大部分沒有被聚合物覆 蓋。 23.如申請專利範圍第22項之可撓性骨複合材料, 其中該第一聚合物層係位於該可撓性骨複合材料的外部, 且主要包括非可再吸收之合成聚合物,及其中該第二聚合 物層係位於該可撓性骨複合材料內部,且主要包括可再吸 收之合成聚合物。 -4-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57861004P | 2004-06-10 | 2004-06-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200609009A TW200609009A (en) | 2006-03-16 |
TWI374036B true TWI374036B (en) | 2012-10-11 |
Family
ID=35385886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW094119113A TWI374036B (en) | 2004-06-10 | 2005-06-09 | Flexible bone composite |
Country Status (12)
Country | Link |
---|---|
US (4) | US8012501B2 (zh) |
EP (2) | EP2308517B1 (zh) |
JP (2) | JP5921796B2 (zh) |
KR (1) | KR100975678B1 (zh) |
CN (2) | CN101018572B (zh) |
AU (1) | AU2005254025B2 (zh) |
BR (1) | BRPI0511957A (zh) |
CA (1) | CA2569982C (zh) |
NZ (1) | NZ552026A (zh) |
TW (1) | TWI374036B (zh) |
WO (1) | WO2005123155A2 (zh) |
ZA (1) | ZA200700213B (zh) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070282443A1 (en) * | 1997-03-07 | 2007-12-06 | Disc-O-Tech Medical Technologies Ltd. | Expandable element |
AU5862199A (en) | 1998-09-11 | 2000-04-03 | Michael Raschke | Biologically active implants |
US7621950B1 (en) | 1999-01-27 | 2009-11-24 | Kyphon Sarl | Expandable intervertebral spacer |
EP1763703A4 (en) * | 2004-05-12 | 2010-12-08 | Massachusetts Inst Technology | MANUFACTURING METHOD, SUCH AS A THREE DIMENSIONAL PRINTING, INCLUDING FORMATION OF FILMS USING SOLVENT VAPOR AND THE LIKE |
TWI374036B (en) * | 2004-06-10 | 2012-10-11 | Sean Kerr | Flexible bone composite |
EP1931401A2 (en) * | 2005-09-09 | 2008-06-18 | University of Arkansas at Little Rock | System and method for tissue generation and bone regeneration |
US8936805B2 (en) | 2005-09-09 | 2015-01-20 | Board Of Trustees Of The University Of Arkansas | Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same |
US9763788B2 (en) | 2005-09-09 | 2017-09-19 | Board Of Trustees Of The University Of Arkansas | Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same |
US8186555B2 (en) | 2006-01-31 | 2012-05-29 | Ethicon Endo-Surgery, Inc. | Motor-driven surgical cutting and fastening instrument with mechanical closure system |
US8708213B2 (en) | 2006-01-31 | 2014-04-29 | Ethicon Endo-Surgery, Inc. | Surgical instrument having a feedback system |
US7845537B2 (en) | 2006-01-31 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Surgical instrument having recording capabilities |
EP3047860A1 (en) | 2006-07-20 | 2016-07-27 | OrbusNeich Medical, Inc. | Bioabsorbable polymeric composition for a medical device |
US8524265B2 (en) * | 2006-08-17 | 2013-09-03 | Warsaw Orthopedic, Inc. | Medical implant sheets useful for tissue regeneration |
US20080063681A1 (en) * | 2006-09-11 | 2008-03-13 | Ebi, L.P. | Therapeutic bone replacement material |
US7959942B2 (en) | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
US8691321B2 (en) | 2006-10-20 | 2014-04-08 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device background |
CA2667213C (en) * | 2006-10-23 | 2015-12-29 | Eth Zurich | Fibrous pharmaceutical and implant materials |
US8684253B2 (en) | 2007-01-10 | 2014-04-01 | Ethicon Endo-Surgery, Inc. | Surgical instrument with wireless communication between a control unit of a robotic system and remote sensor |
EP2190365A4 (en) * | 2007-05-10 | 2013-09-04 | Oren Globerman | CENTROMEDULAR NAIL EXTENSIBLE FOR FIXING A SMALL BONE |
US11564682B2 (en) | 2007-06-04 | 2023-01-31 | Cilag Gmbh International | Surgical stapler device |
US7922767B2 (en) | 2007-07-07 | 2011-04-12 | Jmea Corporation | Disk fusion implant |
WO2009013752A2 (en) * | 2007-07-25 | 2009-01-29 | Depuy Spine, Inc. | Expandable bone filler materials and methods of using same |
US20090130174A1 (en) * | 2007-08-20 | 2009-05-21 | Vanderbilt University | Poly (ester urethane) urea foams with enhanced mechanical and biological properties |
US8573465B2 (en) | 2008-02-14 | 2013-11-05 | Ethicon Endo-Surgery, Inc. | Robotically-controlled surgical end effector system with rotary actuated closure systems |
US11986183B2 (en) | 2008-02-14 | 2024-05-21 | Cilag Gmbh International | Surgical cutting and fastening instrument comprising a plurality of sensors to measure an electrical parameter |
US9770245B2 (en) | 2008-02-15 | 2017-09-26 | Ethicon Llc | Layer arrangements for surgical staple cartridges |
US20110293685A1 (en) * | 2008-10-03 | 2011-12-01 | Trustees Of Tufts College | Scaffolds for tissue engineering and regenerative medicine |
GB0818933D0 (en) * | 2008-10-16 | 2008-11-19 | Depuy Int Ltd | An implantable medical device |
WO2010051032A1 (en) * | 2008-10-31 | 2010-05-06 | Synthes Usa, Llc | Method and device for activating stem cells |
US8778378B2 (en) * | 2009-12-21 | 2014-07-15 | Orthovita, Inc. | Bioactive antibacterial bone graft materials |
US20110208190A1 (en) * | 2010-02-23 | 2011-08-25 | University Of Connecticut | Natural Polymer-Based Porous Orthopedic Fixation Screw for Bone Repair and Regeneration |
US9592050B2 (en) | 2010-09-30 | 2017-03-14 | Ethicon Endo-Surgery, Llc | End effector comprising a distal tissue abutment member |
US20220338870A1 (en) * | 2010-09-30 | 2022-10-27 | Cilag Gmbh International | Tissue thickness compensator comprising a reservoir |
US11849952B2 (en) | 2010-09-30 | 2023-12-26 | Cilag Gmbh International | Staple cartridge comprising staples positioned within a compressible portion thereof |
US9629814B2 (en) | 2010-09-30 | 2017-04-25 | Ethicon Endo-Surgery, Llc | Tissue thickness compensator configured to redistribute compressive forces |
US20220175370A1 (en) * | 2010-09-30 | 2022-06-09 | Cilag Gmbh International | Tissue thickness compensator comprising at least one medicament |
WO2012096965A1 (en) * | 2011-01-10 | 2012-07-19 | Tornier, Inc. | Antibiotic orthopedic devices |
CN103476440B (zh) | 2011-02-25 | 2016-10-19 | 新特斯有限责任公司 | 促进成骨的植入物以及诱导骨生长的方法 |
US10448889B2 (en) * | 2011-04-29 | 2019-10-22 | Medtronic, Inc. | Determining nerve location relative to electrodes |
CA2853213C (en) * | 2011-10-26 | 2019-09-10 | Universiteit Twente | Artificial bone implants, or bone grafts, of polymeric composites with bone forming properties |
US9025757B2 (en) | 2012-03-26 | 2015-05-05 | Satmap International Holdings Limited | Call mapping systems and methods using bayesian mean regression (BMR) |
WO2014110284A1 (en) * | 2013-01-09 | 2014-07-17 | Bacterin International, Inc. | Bone graft substitute containing a temporary contrast agent and a method of generating such and a method of use thereof |
US9579133B2 (en) | 2013-02-01 | 2017-02-28 | James Guthlein | Internal fixation device |
BR112015021098B1 (pt) | 2013-03-01 | 2022-02-15 | Ethicon Endo-Surgery, Inc | Cobertura para uma junta de articulação e instrumento cirúrgico |
CN105283207B (zh) * | 2013-03-15 | 2017-12-01 | 阿肯色大学董事会 | 使用可降解的聚合物基纳米复合材料的骨再生及其应用 |
AT515384B1 (de) * | 2014-02-05 | 2016-04-15 | Dietmar Dr Sonnleitner | Vorverbundene mehrschichtige Folie zur Abdeckung einer Knochendefektstelle |
US9895354B2 (en) | 2014-04-04 | 2018-02-20 | University Of Kentucky Research Foundation | Bilayered calcium sulfate/calcium phosphate space-making composites with multiple drug delivery capabilities |
JP6612256B2 (ja) | 2014-04-16 | 2019-11-27 | エシコン エルエルシー | 不均一な締結具を備える締結具カートリッジ |
EP3203935B1 (en) * | 2014-10-08 | 2019-11-20 | Board of Trustees of the University of Arkansas | Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same |
US9901457B2 (en) | 2014-10-16 | 2018-02-27 | Jmea Corporation | Coiling implantable prostheses |
US9924944B2 (en) | 2014-10-16 | 2018-03-27 | Ethicon Llc | Staple cartridge comprising an adjunct material |
US10376611B2 (en) * | 2015-02-16 | 2019-08-13 | The Royal Institution For The Advancement Of Learning/Mcgill University | Multilayered bone graft and method of making same |
US10349939B2 (en) | 2015-03-25 | 2019-07-16 | Ethicon Llc | Method of applying a buttress to a surgical stapler |
DE102015107600B4 (de) * | 2015-05-13 | 2017-08-10 | Heraeus Medical Gmbh | Partikuläres alloplastisches Knochenersatzmaterial und Verfahren zur Herstellung eines frei geformten porösen Körpers |
US11890015B2 (en) | 2015-09-30 | 2024-02-06 | Cilag Gmbh International | Compressible adjunct with crossing spacer fibers |
US10357247B2 (en) | 2016-04-15 | 2019-07-23 | Ethicon Llc | Surgical instrument with multiple program responses during a firing motion |
CN106245094B (zh) * | 2016-08-19 | 2018-07-03 | 山东大学 | 一种钙磷硅生物陶瓷涂层及其制备方法与应用 |
CN106283154B (zh) * | 2016-08-19 | 2018-07-06 | 山东大学 | 一种两步制备镁合金表面硅钙磷生物陶瓷涂层的方法与应用 |
US10588632B2 (en) | 2016-12-21 | 2020-03-17 | Ethicon Llc | Surgical end effectors and firing members thereof |
US10842490B2 (en) | 2017-10-31 | 2020-11-24 | Ethicon Llc | Cartridge body design with force reduction based on firing completion |
CN108578787A (zh) * | 2018-08-07 | 2018-09-28 | 宁波宝亭生物科技有限公司 | 一种可吸收的骨固定装置及其制备方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4137921A (en) | 1977-06-24 | 1979-02-06 | Ethicon, Inc. | Addition copolymers of lactide and glycolide and method of preparation |
DE2733394C3 (de) * | 1977-07-23 | 1984-10-25 | Riess, Guido, Prof. Dr.med.dent., 8100 Garmisch-Partenkirchen | Kunstzahn mit implantierbarer Zahnwurzel |
FI80605C (fi) * | 1986-11-03 | 1990-07-10 | Biocon Oy | Benkirurgisk biokompositmaterial. |
DE3831657A1 (de) * | 1988-09-17 | 1990-03-22 | Boehringer Ingelheim Kg | Vorrichtung zur osteosynthese und verfahren zu ihrer herstellung |
JPH02241460A (ja) * | 1989-03-16 | 1990-09-26 | Asahi Optical Co Ltd | 骨修復用複合材料 |
JPH0385179A (ja) | 1989-08-30 | 1991-04-10 | Sumitomo Bakelite Co Ltd | 医療用バルーンカテーテル |
JPH04221538A (ja) | 1990-12-21 | 1992-08-12 | Olympus Optical Co Ltd | 穿刺装置 |
CA2035701C (en) | 1991-02-05 | 1999-01-19 | Karl T. Chuang | Active liquid distributor containing, packed column |
EP0526682B1 (de) * | 1991-08-07 | 1997-03-05 | Oscobal Ag | Endoprothese mit einem Metalldrahtwerk |
US5380328A (en) * | 1993-08-09 | 1995-01-10 | Timesh, Inc. | Composite perforated implant structures |
US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
US5626861A (en) * | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
DE4414675C1 (de) * | 1994-04-27 | 1995-09-28 | Kirsch Axel | Abdeckeinrichtung für Knochendefektstellen und Verfahren zu deren Herstellung |
JP3125579B2 (ja) | 1994-05-24 | 2001-01-22 | 三菱マテリアル株式会社 | 生体用セメント充填装置 |
JP3046716B2 (ja) | 1994-05-27 | 2000-05-29 | ウシオ電機株式会社 | 空気殺菌装置 |
JP3250127B2 (ja) | 1994-07-14 | 2002-01-28 | 三菱マテリアル株式会社 | 生体用セメント注入治具 |
US5639402A (en) * | 1994-08-08 | 1997-06-17 | Barlow; Joel W. | Method for fabricating artificial bone implant green parts |
US5700559A (en) * | 1994-12-16 | 1997-12-23 | Advanced Surface Technology | Durable hydrophilic surface coatings |
US5716413A (en) * | 1995-10-11 | 1998-02-10 | Osteobiologics, Inc. | Moldable, hand-shapable biodegradable implant material |
JPH09201330A (ja) | 1996-01-25 | 1997-08-05 | Nissho Corp | ドレナージチューブ組立体 |
EP0907338A4 (en) | 1996-04-01 | 1999-09-01 | American Cyanamid Co | CRYSTALLINE COPOLYMERS AND PROCESS FOR PRODUCING SUCH COPOLYMERS |
US5919234A (en) * | 1996-08-19 | 1999-07-06 | Macropore, Inc. | Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration |
FI103581B1 (fi) | 1996-11-11 | 1999-07-30 | Neste Oy | Menetelmä polyhydroksihappojen valmistamiseksi |
US5866155A (en) * | 1996-11-20 | 1999-02-02 | Allegheny Health, Education And Research Foundation | Methods for using microsphere polymers in bone replacement matrices and composition produced thereby |
DE19721661A1 (de) | 1997-05-23 | 1998-11-26 | Zimmer Markus | Knochen- und Knorpel Ersatzstrukturen |
WO1999049819A1 (en) * | 1998-04-01 | 1999-10-07 | Parallax Medical, Inc. | Pressure applicator for hard tissue implant placement |
US5968253A (en) * | 1998-07-31 | 1999-10-19 | Norian Corporation | Calcium phosphate cements comprising antimicrobial agents |
JP2000126280A (ja) * | 1998-08-18 | 2000-05-09 | Asahi Optical Co Ltd | 骨補填用シートの製造方法および骨補填用シート |
US6350284B1 (en) * | 1998-09-14 | 2002-02-26 | Bionx Implants, Oy | Bioabsorbable, layered composite material for guided bone tissue regeneration |
US6387414B1 (en) * | 1999-08-05 | 2002-05-14 | Nof Corporation | Method for preparing hydroxyapatite composite and biocompatible material |
WO2000071178A1 (fr) * | 1999-05-19 | 2000-11-30 | Ecole Polytechnique Federale De Lausanne (Epfl) | Substitut osseux de type phosphate de calcium |
ATE257397T1 (de) | 1999-10-29 | 2004-01-15 | Univ Drexel | Bindende hydrogele zum ersatz des nukleus pulposus |
US6811776B2 (en) * | 2000-12-27 | 2004-11-02 | The Regents Of The University Of Michigan | Process for ex vivo formation of mammalian bone and uses thereof |
AU2001270153B2 (en) * | 2000-07-03 | 2006-07-06 | Osteotech, Inc. | Osteogenic implants derived from bone |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
KR100383433B1 (ko) | 2001-06-29 | 2003-05-12 | 주식회사 씨엠리서치 | 고강도 뼈 고정용 생분해성 유기 고분자/무기 복합 소재의제조 방법 및 그에 의해 제조된 생분해성 유기고분자/무기 복합 소재 |
JP2003210570A (ja) * | 2002-01-18 | 2003-07-29 | Olympus Optical Co Ltd | 生体活性層を有するインプラント材およびインプラント基材への生体活性層の被覆方法 |
CN100523082C (zh) | 2002-01-31 | 2009-08-05 | 石宗利 | 高强度高模量可吸收性骨内固定复合材料及制备方法 |
JP2004041313A (ja) * | 2002-07-09 | 2004-02-12 | Pentax Corp | リン酸カルシウムブロックを含むリン酸カルシウム−合成樹脂複合体及びその製造方法 |
WO2004032988A2 (en) | 2002-10-08 | 2004-04-22 | Osteotech, Inc. | Coupling agents for orthopedic biomaterials |
WO2005000483A1 (en) | 2003-06-06 | 2005-01-06 | Tufts University | Method for forming inorganic coatings |
JP4674315B2 (ja) * | 2004-02-19 | 2011-04-20 | 川澄化学工業株式会社 | 骨誘導再生膜材料 |
US20050216008A1 (en) * | 2004-03-24 | 2005-09-29 | Zwirnmann Ralph F | Bone fixation implants |
TWI374036B (en) | 2004-06-10 | 2012-10-11 | Sean Kerr | Flexible bone composite |
DE102006012655B4 (de) | 2006-01-10 | 2008-12-24 | Siemens Ag | Verfahren zum Bereitstellen einer Dienstqualität in einem WiMAX-Kommunikationsnetzwerk und Verfahren zum Auswählen einer Zugangs-Transportressourcenkontrollfunktion durch eine Richtlinienentscheidungsfunktion in einem Kommunikationsnetzwerk |
-
2005
- 2005-06-09 TW TW094119113A patent/TWI374036B/zh active
- 2005-06-09 US US11/148,193 patent/US8012501B2/en active Active
- 2005-06-10 EP EP10011367.9A patent/EP2308517B1/en active Active
- 2005-06-10 ZA ZA200700213A patent/ZA200700213B/en unknown
- 2005-06-10 CA CA2569982A patent/CA2569982C/en active Active
- 2005-06-10 BR BRPI0511957-0A patent/BRPI0511957A/pt not_active Application Discontinuation
- 2005-06-10 CN CN2005800271977A patent/CN101018572B/zh active Active
- 2005-06-10 JP JP2007527764A patent/JP5921796B2/ja active Active
- 2005-06-10 CN CN201110355210.9A patent/CN102406964B/zh active Active
- 2005-06-10 WO PCT/US2005/020484 patent/WO2005123155A2/en active Application Filing
- 2005-06-10 EP EP05760224.5A patent/EP1753475B1/en active Active
- 2005-06-10 AU AU2005254025A patent/AU2005254025B2/en active Active
- 2005-06-10 KR KR1020067026310A patent/KR100975678B1/ko active IP Right Grant
- 2005-06-10 NZ NZ552026A patent/NZ552026A/en unknown
-
2011
- 2011-06-07 JP JP2011127249A patent/JP2011218183A/ja active Pending
- 2011-08-12 US US13/208,837 patent/US8221782B2/en active Active
-
2012
- 2012-07-02 US US13/539,779 patent/US8420108B2/en active Active
-
2013
- 2013-03-15 US US13/838,629 patent/US8771721B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2005254025B2 (en) | 2011-06-16 |
EP2308517B1 (en) | 2018-09-05 |
CN102406964A (zh) | 2012-04-11 |
TW200609009A (en) | 2006-03-16 |
NZ552026A (en) | 2010-09-30 |
JP2011218183A (ja) | 2011-11-04 |
US20110300194A1 (en) | 2011-12-08 |
CA2569982A1 (en) | 2005-12-29 |
US8771721B2 (en) | 2014-07-08 |
EP1753475A2 (en) | 2007-02-21 |
CN102406964B (zh) | 2015-08-05 |
EP2308517A3 (en) | 2011-08-10 |
CN101018572B (zh) | 2011-12-28 |
US8221782B2 (en) | 2012-07-17 |
CN101018572A (zh) | 2007-08-15 |
AU2005254025A1 (en) | 2005-12-29 |
BRPI0511957A (pt) | 2008-01-22 |
JP5921796B2 (ja) | 2016-05-24 |
JP2008502455A (ja) | 2008-01-31 |
WO2005123155A3 (en) | 2006-02-02 |
US20060008504A1 (en) | 2006-01-12 |
KR100975678B1 (ko) | 2010-08-12 |
WO2005123155A2 (en) | 2005-12-29 |
EP2308517A2 (en) | 2011-04-13 |
CA2569982C (en) | 2013-10-15 |
US20120269873A1 (en) | 2012-10-25 |
US20130209526A1 (en) | 2013-08-15 |
KR20070041448A (ko) | 2007-04-18 |
ZA200700213B (en) | 2008-05-28 |
US8420108B2 (en) | 2013-04-16 |
US8012501B2 (en) | 2011-09-06 |
EP1753475B1 (en) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI374036B (en) | Flexible bone composite | |
US20050220837A1 (en) | Antimicrobial hyaluronic acid coatings for orthopedic implants | |
EP1663333B1 (en) | Bone cement compositions having fiber-reinforcement and/or increased flowability | |
ZA200602482B (en) | Bone cement compositions having fiber-reinforcement and/or increased flowability | |
AU2013216614B2 (en) | Flexible bone composite |